Author: Ravi Shankar

AS Inbank has decided to exit the Czech market and intends to discontinue new sales by 1 January 2027, gradually running off its existing portfolio. Czechia accounts for less than 4% of Inbank’s total loan and rental portfolio, and the exit will not have a material impact on the Group’s financial standing.

Inbank started operations in the Czech market in October 2022. Following four years of operations, investment, and business development initiatives, Inbank has concluded that the market structure, characterized by the dominant role of large universal banks and financial advisors, does not provide the conditions for its merchant-based business model to achieve sustainable growth and targeted return on capital. 

Priit Põldoja, CEO of Inbank, comments:

“Despite our best efforts and our proven technology and products we brought to the Czech market, our experience has taught us that the market is not the right fit for our business model. This decision allows us to concentrate our resources on growing our profitable businesses, developing new products, and pursuing opportunities in markets where we see a stronger strategic fit. Our joint venture with Eurobank in Greece is a strong example of this approach, where we will continue to focus on launching the business in early 2027.” 

Existing customer agreements will remain unchanged, and Inbank will continue to service its Czech customers until all agreements have ended and all outstanding obligations have been fulfilled. Merchant partners will be contacted individually regarding the termination of cooperation in accordance with the terms of their agreements.

For the time being, Inbank will continue to operate in Czechia as a branch of AS Inbank while evaluating alternative operating structures. Inbank will decide on the future structure during 2027, in dialogue with the Estonian and Czech regulators, and share further updates as the process progresses.

The exit will involve a reduction of the Czech team to the size that is optimal to continue offering quality service to existing customers and partners and manage the portfolio run-off.

Inbank is a financial technology company with an EU banking license that connects merchants, consumers and financial institutions on its next generation embedded finance platform. Partnering with more than 6,000 merchants, Inbank has 787,000+ active contracts and collects deposits across seven markets in Europe. Inbank bonds are listed on the Nasdaq Tallinn Stock Exchange.

Additional information:

Styv Solovjov
Head of Investor Relations
+372 5645 9738
styv.solovjov@inbank.ee

Merit Arva
Head of Corporate Communications
+372 553 3550
press@inbank.ee

New insider filings show continued open-market buying by CEO Amir Heshmatpour, while the company prepares to discuss a potential accelerated approval strategy and Phase 3 trial design with regulators

DENVER, Nov. 12, 2026 (GLOBE NEWSWIRE) — (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading into a potentially important period for its clinical programs, with additional insider purchases coinciding with a newly announced FDA meeting that could help determine the development pathway for its investigational brain cancer therapy, NEO100.

Two Form 4 filings dated November 12 add important detail to the company’s recent insider-buying activity. CEO Amir F. Heshmatpour reported purchasing 80,000 shares across November 19-11, including 50,000 shares at a weighted average price of $4.192, another 10,000 shares at $4.49, 10,000 shares at $4.00, and 10,000 shares at $3.86. The reported transactions represent approximately $333,100 in additional open-market purchases. His directly held common stock position increased to 3,333,000 shares following the transactions.

The latest filing follows a series of purchases throughout 2026, with the updated total 2026 purchases hitting approximately 341,000 shares.

The latest filings also show buying by another senior insider. Thomas C. Chen, the company’s Chief Medical Officer, reported purchasing 2,732 shares on November 9 at $3.66 and another 2,284 shares on November 10 at a weighted average price of $4.379. The combined 5,016 shares represent approximately $20,000 in purchases through his IRA.

FDA meeting moves NEO100 toward a more defined regulatory discussion

The most significant recent development may be NeOnc’s November 11 announcement that the FDA granted a Type B End-of-Phase meeting, scheduled for early January 2027, to discuss a potential accelerated approval pathway for intranasal NEO100.

This is more consequential than a routine regulatory update because the company intends to ask the FDA whether its existing clinical and nonclinical package could support a 505(b)(2) New Drug Application seeking accelerated approval under Section 506(c) of the Federal Food, Drug, and Cosmetic Act.

NeOnc also plans to seek agreement on the design of NEO100-012, a proposed multicenter, randomized, controlled Phase 3 study. The company describes the proposed trial as a comparison of intranasal NEO100 against investigator’s-choice standard-of-care chemotherapy in patients with recurrent or progressive IDH-mutant grade 4 astrocytoma. Overall survival would serve as the primary endpoint.

Under the company’s proposed strategy, a confirmatory Phase 3 trial would be underway, with enrollment ongoing, at the time of any accelerated-approval application. Its final overall survival analysis would then be intended to verify clinical benefit and support conversion to traditional approval.

NeOnc also intends to discuss the adequacy of its nonclinical safety package, the scientific bridge between published perillyl alcohol research and its intranasal formulation, and potential eligibility for Breakthrough Therapy designation.

These are important questions because regulatory feedback could influence the size, design, timing and cost of the next clinical-development stage.

The company has said it expects to provide an update after receiving and reviewing the FDA’s official meeting minutes.

November 13 presentations could provide additional clinical detail

Another near-term catalyst is the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), taking place November 12–15 in Philadelphia. NeOnc has announced two poster presentations scheduled for Friday, November 13, from 7:30 to 9:30 p.m. Eastern.

The first presentation, abstract CTNI-26, is titled “Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma: Updated Results from a Phase 1/2a Study and Compassionate Use Experience.”

Presented by Thomas C. Chen, MD, PhD, the poster is particularly relevant because it is intended to provide updated results combining the Phase 1/2a experience with compassionate-use observations. Investors and clinicians will be looking for additional information about the duration of responses, survival outcomes, patient characteristics and the consistency of the reported clinical experience.

The second presentation, abstract CTNI-27, is titled “Oral NEO212 in TMZ-Resistant Recurrent GBM and Brain Metastases: Phase 1 Safety, PK, and Early Signals of Activity.”

Presented by Josh Neman, PhD, the poster will address Phase 1 safety, pharmacokinetics and early signals of activity for NEO212, an investigational oral conjugate of temozolomide and perillyl alcohol.

This presentation matters because NEO212 represents a separate development opportunity from NEO100. While NEO100 is being evaluated as an intranasal therapy, NEO212 is designed as an oral approach for central nervous system cancers, including recurrent glioblastoma.

The clinical case: promising Phase 2a results

The regulatory discussion follows NeOnc’s August 12 announcement of topline Phase 2a results for NEO100 in recurrent or progressive IDH1-mutant high-grade glioma.

NeOnc reported that the study achieved six-month progression-free survival of 48.9%, compared with a prespecified historical benchmark of 20%, with a reported p-value of 0.0047. Median overall survival was 26.09 months, and 86.7% of patients were alive at six months.

The company reported no major toxicities across the cohort, with adverse events predominantly low-grade.

These results are relevant because recurrent IDH-mutant high-grade glioma remains a serious treatment challenge, and the company is seeking to develop an approach that delivers therapy intranasally rather than relying exclusively on conventional systemic administration.

NEO100 is a highly purified form of perillyl alcohol. Its intranasal delivery approach is designed to provide a non-invasive route to the brain.

Analyst coverage provides a key dimension to the investment picture

BTIG reiterated its Buy rating and maintained the $15 price target for NeOnc, reflecting continued confidence in the company’s technology platform and clinical development opportunities. BTIG originally initiated coverage in April 2026, highlighting the potential of perillyl alcohol (POH) to improve drug delivery to the central nervous system, including its potential applications in glioblastoma and other aggressive brain cancers. The firm’s research identified additional clinical data from NEO100 and NEO212 as important catalysts for the investment outlook.

BTIG is not alone in maintaining a positive view of NeOnc. Roth MKM analyst Jonathan Aschoff carries a Buy rating and $20 price target, Maxim Group analyst Jason McCarthy maintains a Buy rating and $20 target, while Alliance Global Partners analyst Matthew Venezia has a Buy rating and $13 target. This represents four analyst firms with Buy ratings and price targets ranging from $13 to $20. While analyst targets are opinions rather than predictions or guarantees of future performance, the coverage highlights the expectations being placed on NeOnc’s upcoming clinical and regulatory milestones.

The short-interest angle adds another dimension

NTHI has also attracted attention from market participants tracking short interest.

The October 30 reporting period shows that the short interest has grown toto over 920,000 shares and over 7 days to cover, and it remains over 5 days to cover based on the corresponding average trading volume.

The company’s relatively limited reported float compared with total shares outstanding is also relevant to potential volatility.

Abu Dhabi collaboration adds an international dimension

NeOnc has also announced a memorandum of understanding with the Department of Health – Abu Dhabi, signed in October 2026.

The proposed collaboration covers scientific exchange, specialist training, real-world evidence and an assessment of potential clinical trial opportunities in the emirate. The parties also intend to explore the possibility of a regional presence and future manufacturing, supply or distribution activities.

The company previously disclosed that two children in Abu Dhabi were receiving investigational NEO100 through its Compassionate Care program, with a third expected at the time of the announcement.

The agreement could create opportunities to expand clinical research and institutional relationships, particularly in pediatric oncology.

What investors should watch next

The coming weeks and months provide several identifiable milestones:

• November 13, 2026: Updated NEO100 Phase 1/2a and compassionate-use data, alongside NEO212 Phase 1 safety, pharmacokinetic and early activity findings, at the SNO Annual Meeting.
• Early January 2027: FDA Type B End-of-Phase meeting covering the potential accelerated approval pathway, proposed Phase 3 design, nonclinical safety package, scientific bridging and possible Breakthrough Therapy designation.
• Following the FDA meeting: Publication and review of official FDA meeting minutes, which should provide greater clarity on regulatory feedback and the proposed clinical-development strategy.
• Subsequent development: Progress toward the proposed NEO100-012 randomized Phase 3 trial, including final protocol requirements, funding, site activation and enrollment plans.

About 247MarketNews

In today’s fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication.  Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
247MarketNews
Editor@247marketnews.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

New insider filings show continued open-market buying by CEO Amir Heshmatpour, while the company prepares to discuss a potential accelerated approval strategy and Phase 3 trial design with regulators

DENVER, Nov. 12, 2026 (GLOBE NEWSWIRE) — (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading into a potentially important period for its clinical programs, with additional insider purchases coinciding with a newly announced FDA meeting that could help determine the development pathway for its investigational brain cancer therapy, NEO100.

Two Form 4 filings dated November 12 add important detail to the company’s recent insider-buying activity. CEO Amir F. Heshmatpour reported purchasing 80,000 shares across November 19-11, including 50,000 shares at a weighted average price of $4.192, another 10,000 shares at $4.49, 10,000 shares at $4.00, and 10,000 shares at $3.86. The reported transactions represent approximately $333,100 in additional open-market purchases. His directly held common stock position increased to 3,333,000 shares following the transactions.

The latest filing follows a series of purchases throughout 2026, with the updated total 2026 purchases hitting approximately 341,000 shares.

The latest filings also show buying by another senior insider. Thomas C. Chen, the company’s Chief Medical Officer, reported purchasing 2,732 shares on November 9 at $3.66 and another 2,284 shares on November 10 at a weighted average price of $4.379. The combined 5,016 shares represent approximately $20,000 in purchases through his IRA.

FDA meeting moves NEO100 toward a more defined regulatory discussion

The most significant recent development may be NeOnc’s November 11 announcement that the FDA granted a Type B End-of-Phase meeting, scheduled for early January 2027, to discuss a potential accelerated approval pathway for intranasal NEO100.

This is more consequential than a routine regulatory update because the company intends to ask the FDA whether its existing clinical and nonclinical package could support a 505(b)(2) New Drug Application seeking accelerated approval under Section 506(c) of the Federal Food, Drug, and Cosmetic Act.

NeOnc also plans to seek agreement on the design of NEO100-012, a proposed multicenter, randomized, controlled Phase 3 study. The company describes the proposed trial as a comparison of intranasal NEO100 against investigator’s-choice standard-of-care chemotherapy in patients with recurrent or progressive IDH-mutant grade 4 astrocytoma. Overall survival would serve as the primary endpoint.

Under the company’s proposed strategy, a confirmatory Phase 3 trial would be underway, with enrollment ongoing, at the time of any accelerated-approval application. Its final overall survival analysis would then be intended to verify clinical benefit and support conversion to traditional approval.

NeOnc also intends to discuss the adequacy of its nonclinical safety package, the scientific bridge between published perillyl alcohol research and its intranasal formulation, and potential eligibility for Breakthrough Therapy designation.

These are important questions because regulatory feedback could influence the size, design, timing and cost of the next clinical-development stage.

The company has said it expects to provide an update after receiving and reviewing the FDA’s official meeting minutes.

November 13 presentations could provide additional clinical detail

Another near-term catalyst is the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), taking place November 12–15 in Philadelphia. NeOnc has announced two poster presentations scheduled for Friday, November 13, from 7:30 to 9:30 p.m. Eastern.

The first presentation, abstract CTNI-26, is titled “Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma: Updated Results from a Phase 1/2a Study and Compassionate Use Experience.”

Presented by Thomas C. Chen, MD, PhD, the poster is particularly relevant because it is intended to provide updated results combining the Phase 1/2a experience with compassionate-use observations. Investors and clinicians will be looking for additional information about the duration of responses, survival outcomes, patient characteristics and the consistency of the reported clinical experience.

The second presentation, abstract CTNI-27, is titled “Oral NEO212 in TMZ-Resistant Recurrent GBM and Brain Metastases: Phase 1 Safety, PK, and Early Signals of Activity.”

Presented by Josh Neman, PhD, the poster will address Phase 1 safety, pharmacokinetics and early signals of activity for NEO212, an investigational oral conjugate of temozolomide and perillyl alcohol.

This presentation matters because NEO212 represents a separate development opportunity from NEO100. While NEO100 is being evaluated as an intranasal therapy, NEO212 is designed as an oral approach for central nervous system cancers, including recurrent glioblastoma.

The clinical case: promising Phase 2a results

The regulatory discussion follows NeOnc’s August 12 announcement of topline Phase 2a results for NEO100 in recurrent or progressive IDH1-mutant high-grade glioma.

NeOnc reported that the study achieved six-month progression-free survival of 48.9%, compared with a prespecified historical benchmark of 20%, with a reported p-value of 0.0047. Median overall survival was 26.09 months, and 86.7% of patients were alive at six months.

The company reported no major toxicities across the cohort, with adverse events predominantly low-grade.

These results are relevant because recurrent IDH-mutant high-grade glioma remains a serious treatment challenge, and the company is seeking to develop an approach that delivers therapy intranasally rather than relying exclusively on conventional systemic administration.

NEO100 is a highly purified form of perillyl alcohol. Its intranasal delivery approach is designed to provide a non-invasive route to the brain.

Analyst coverage provides a key dimension to the investment picture

BTIG reiterated its Buy rating and maintained the $15 price target for NeOnc, reflecting continued confidence in the company’s technology platform and clinical development opportunities. BTIG originally initiated coverage in April 2026, highlighting the potential of perillyl alcohol (POH) to improve drug delivery to the central nervous system, including its potential applications in glioblastoma and other aggressive brain cancers. The firm’s research identified additional clinical data from NEO100 and NEO212 as important catalysts for the investment outlook.

BTIG is not alone in maintaining a positive view of NeOnc. Roth MKM analyst Jonathan Aschoff carries a Buy rating and $20 price target, Maxim Group analyst Jason McCarthy maintains a Buy rating and $20 target, while Alliance Global Partners analyst Matthew Venezia has a Buy rating and $13 target. This represents four analyst firms with Buy ratings and price targets ranging from $13 to $20. While analyst targets are opinions rather than predictions or guarantees of future performance, the coverage highlights the expectations being placed on NeOnc’s upcoming clinical and regulatory milestones.

The short-interest angle adds another dimension

NTHI has also attracted attention from market participants tracking short interest.

The October 30 reporting period shows that the short interest has grown toto over 920,000 shares and over 7 days to cover, and it remains over 5 days to cover based on the corresponding average trading volume.

The company’s relatively limited reported float compared with total shares outstanding is also relevant to potential volatility.

Abu Dhabi collaboration adds an international dimension

NeOnc has also announced a memorandum of understanding with the Department of Health – Abu Dhabi, signed in October 2026.

The proposed collaboration covers scientific exchange, specialist training, real-world evidence and an assessment of potential clinical trial opportunities in the emirate. The parties also intend to explore the possibility of a regional presence and future manufacturing, supply or distribution activities.

The company previously disclosed that two children in Abu Dhabi were receiving investigational NEO100 through its Compassionate Care program, with a third expected at the time of the announcement.

The agreement could create opportunities to expand clinical research and institutional relationships, particularly in pediatric oncology.

What investors should watch next

The coming weeks and months provide several identifiable milestones:

• November 13, 2026: Updated NEO100 Phase 1/2a and compassionate-use data, alongside NEO212 Phase 1 safety, pharmacokinetic and early activity findings, at the SNO Annual Meeting.
• Early January 2027: FDA Type B End-of-Phase meeting covering the potential accelerated approval pathway, proposed Phase 3 design, nonclinical safety package, scientific bridging and possible Breakthrough Therapy designation.
• Following the FDA meeting: Publication and review of official FDA meeting minutes, which should provide greater clarity on regulatory feedback and the proposed clinical-development strategy.
• Subsequent development: Progress toward the proposed NEO100-012 randomized Phase 3 trial, including final protocol requirements, funding, site activation and enrollment plans.

About 247MarketNews

In today’s fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication.  Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
247MarketNews
Editor@247marketnews.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

New insider filings show continued open-market buying by CEO Amir Heshmatpour, while the company prepares to discuss a potential accelerated approval strategy and Phase 3 trial design with regulators

DENVER, Nov. 12, 2026 (GLOBE NEWSWIRE) — (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading into a potentially important period for its clinical programs, with additional insider purchases coinciding with a newly announced FDA meeting that could help determine the development pathway for its investigational brain cancer therapy, NEO100.

Two Form 4 filings dated November 12 add important detail to the company’s recent insider-buying activity. CEO Amir F. Heshmatpour reported purchasing 80,000 shares across November 19-11, including 50,000 shares at a weighted average price of $4.192, another 10,000 shares at $4.49, 10,000 shares at $4.00, and 10,000 shares at $3.86. The reported transactions represent approximately $333,100 in additional open-market purchases. His directly held common stock position increased to 3,333,000 shares following the transactions.

The latest filing follows a series of purchases throughout 2026, with the updated total 2026 purchases hitting approximately 341,000 shares.

The latest filings also show buying by another senior insider. Thomas C. Chen, the company’s Chief Medical Officer, reported purchasing 2,732 shares on November 9 at $3.66 and another 2,284 shares on November 10 at a weighted average price of $4.379. The combined 5,016 shares represent approximately $20,000 in purchases through his IRA.

FDA meeting moves NEO100 toward a more defined regulatory discussion

The most significant recent development may be NeOnc’s November 11 announcement that the FDA granted a Type B End-of-Phase meeting, scheduled for early January 2027, to discuss a potential accelerated approval pathway for intranasal NEO100.

This is more consequential than a routine regulatory update because the company intends to ask the FDA whether its existing clinical and nonclinical package could support a 505(b)(2) New Drug Application seeking accelerated approval under Section 506(c) of the Federal Food, Drug, and Cosmetic Act.

NeOnc also plans to seek agreement on the design of NEO100-012, a proposed multicenter, randomized, controlled Phase 3 study. The company describes the proposed trial as a comparison of intranasal NEO100 against investigator’s-choice standard-of-care chemotherapy in patients with recurrent or progressive IDH-mutant grade 4 astrocytoma. Overall survival would serve as the primary endpoint.

Under the company’s proposed strategy, a confirmatory Phase 3 trial would be underway, with enrollment ongoing, at the time of any accelerated-approval application. Its final overall survival analysis would then be intended to verify clinical benefit and support conversion to traditional approval.

NeOnc also intends to discuss the adequacy of its nonclinical safety package, the scientific bridge between published perillyl alcohol research and its intranasal formulation, and potential eligibility for Breakthrough Therapy designation.

These are important questions because regulatory feedback could influence the size, design, timing and cost of the next clinical-development stage.

The company has said it expects to provide an update after receiving and reviewing the FDA’s official meeting minutes.

November 13 presentations could provide additional clinical detail

Another near-term catalyst is the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), taking place November 12–15 in Philadelphia. NeOnc has announced two poster presentations scheduled for Friday, November 13, from 7:30 to 9:30 p.m. Eastern.

The first presentation, abstract CTNI-26, is titled “Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma: Updated Results from a Phase 1/2a Study and Compassionate Use Experience.”

Presented by Thomas C. Chen, MD, PhD, the poster is particularly relevant because it is intended to provide updated results combining the Phase 1/2a experience with compassionate-use observations. Investors and clinicians will be looking for additional information about the duration of responses, survival outcomes, patient characteristics and the consistency of the reported clinical experience.

The second presentation, abstract CTNI-27, is titled “Oral NEO212 in TMZ-Resistant Recurrent GBM and Brain Metastases: Phase 1 Safety, PK, and Early Signals of Activity.”

Presented by Josh Neman, PhD, the poster will address Phase 1 safety, pharmacokinetics and early signals of activity for NEO212, an investigational oral conjugate of temozolomide and perillyl alcohol.

This presentation matters because NEO212 represents a separate development opportunity from NEO100. While NEO100 is being evaluated as an intranasal therapy, NEO212 is designed as an oral approach for central nervous system cancers, including recurrent glioblastoma.

The clinical case: promising Phase 2a results

The regulatory discussion follows NeOnc’s August 12 announcement of topline Phase 2a results for NEO100 in recurrent or progressive IDH1-mutant high-grade glioma.

NeOnc reported that the study achieved six-month progression-free survival of 48.9%, compared with a prespecified historical benchmark of 20%, with a reported p-value of 0.0047. Median overall survival was 26.09 months, and 86.7% of patients were alive at six months.

The company reported no major toxicities across the cohort, with adverse events predominantly low-grade.

These results are relevant because recurrent IDH-mutant high-grade glioma remains a serious treatment challenge, and the company is seeking to develop an approach that delivers therapy intranasally rather than relying exclusively on conventional systemic administration.

NEO100 is a highly purified form of perillyl alcohol. Its intranasal delivery approach is designed to provide a non-invasive route to the brain.

Analyst coverage provides a key dimension to the investment picture

BTIG reiterated its Buy rating and maintained the $15 price target for NeOnc, reflecting continued confidence in the company’s technology platform and clinical development opportunities. BTIG originally initiated coverage in April 2026, highlighting the potential of perillyl alcohol (POH) to improve drug delivery to the central nervous system, including its potential applications in glioblastoma and other aggressive brain cancers. The firm’s research identified additional clinical data from NEO100 and NEO212 as important catalysts for the investment outlook.

BTIG is not alone in maintaining a positive view of NeOnc. Roth MKM analyst Jonathan Aschoff carries a Buy rating and $20 price target, Maxim Group analyst Jason McCarthy maintains a Buy rating and $20 target, while Alliance Global Partners analyst Matthew Venezia has a Buy rating and $13 target. This represents four analyst firms with Buy ratings and price targets ranging from $13 to $20. While analyst targets are opinions rather than predictions or guarantees of future performance, the coverage highlights the expectations being placed on NeOnc’s upcoming clinical and regulatory milestones.

The short-interest angle adds another dimension

NTHI has also attracted attention from market participants tracking short interest.

The October 30 reporting period shows that the short interest has grown toto over 920,000 shares and over 7 days to cover, and it remains over 5 days to cover based on the corresponding average trading volume.

The company’s relatively limited reported float compared with total shares outstanding is also relevant to potential volatility.

Abu Dhabi collaboration adds an international dimension

NeOnc has also announced a memorandum of understanding with the Department of Health – Abu Dhabi, signed in October 2026.

The proposed collaboration covers scientific exchange, specialist training, real-world evidence and an assessment of potential clinical trial opportunities in the emirate. The parties also intend to explore the possibility of a regional presence and future manufacturing, supply or distribution activities.

The company previously disclosed that two children in Abu Dhabi were receiving investigational NEO100 through its Compassionate Care program, with a third expected at the time of the announcement.

The agreement could create opportunities to expand clinical research and institutional relationships, particularly in pediatric oncology.

What investors should watch next

The coming weeks and months provide several identifiable milestones:

• November 13, 2026: Updated NEO100 Phase 1/2a and compassionate-use data, alongside NEO212 Phase 1 safety, pharmacokinetic and early activity findings, at the SNO Annual Meeting.
• Early January 2027: FDA Type B End-of-Phase meeting covering the potential accelerated approval pathway, proposed Phase 3 design, nonclinical safety package, scientific bridging and possible Breakthrough Therapy designation.
• Following the FDA meeting: Publication and review of official FDA meeting minutes, which should provide greater clarity on regulatory feedback and the proposed clinical-development strategy.
• Subsequent development: Progress toward the proposed NEO100-012 randomized Phase 3 trial, including final protocol requirements, funding, site activation and enrollment plans.

About 247MarketNews

In today’s fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication.  Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
247MarketNews
Editor@247marketnews.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Quarterly Net Income Triples to $3.2 Million as Capital Reallocation Lifts Fleet TCE 37%

Further Expands Capesize Fleet; Fixes M/V Dukeship and M/V Squireship for 2027 at Attractive Charter Rates

Highlights (in million USD, except EPS, LPS and TCE)	Q3 2026		Q3 2025		9M 2026		9M 2025			9M 2026 vs 9M 2025
Net Revenues	$	12.0	$	11.0	$	29.9	$	31.2
Net Income / (Loss)	$	3.2	$	1.1	$	4.2	$	(2.4	)
Adjusted Net Income / (Loss)1	$	4.0	$	1.6	$	5.7	$	(2.6	)
EBITDA1	$	7.2	$	4.9	$	15.0	$	11.5		+30	%
Adjusted EBITDA1	$	8.0	$	5.4	$	16.4	$	11.4		+45	%
TCE2	$	20,737	$	15,093	$	18,446	$	13,436		+37	%
Earnings / (Loss) per share Basic	$	0.34	$	0.12	$	0.46	$	(0.27	)
Earnings / (Loss) per share Diluted	$	0.31	$	0.12	$	0.43	$	(0.27	)
Adjusted Earnings / (Loss) per share Basic1	$	0.43	$	0.18	$	0.62	$	(0.29	)
Adjusted Earnings / (Loss) per share Diluted1	$	0.38	$	0.18	$	0.58	$	(0.29	)

Other Highlights and Developments:

• Strong Third Quarter Financial Performance Reflecting Benefits of Strategic Fleet Repositioning
  • Quarterly Net Income of $3.2 million and Adjusted EBITDA of $8.0 million, with fleet TCE increasing 37% year-over-year to $20,737 per day.
  • Nine-month Adjusted EBITDA increased 45% to $16.4 million, with fleet TCE up 37% to $18,446 per day.
• Cash Dividend for the Third Quarter Doubled to $0.20 Per Share
  • 16^th consecutive quarterly dividend, bringing cumulative cash distributions since November 2022 to $2.24 per share, or approximately $18.7 million.³
• Continued Capital Reallocation Through Further Capesize Expansion
  • Agreed to acquire the 2009-built Capesize vessel M/V Friendship, with delivery expected in early Q1 2027.
  • Completed the sale of the 2011-built Panamax M/V Exelixsea, generating $8.7 million of net cash proceeds and a gain of $1.8 million.

_______________
¹ Adjusted Earnings / (Loss) per share, Adjusted Net Income / (Loss), EBITDA and Adjusted EBITDA are non-GAAP measures. Please see the reconciliation below of Adjusted Earnings / (Loss) per share, Adjusted Net Income / (loss), EBITDA and Adjusted EBITDA to Net Income / (Loss), the most directly comparable U.S. GAAP measure.
² Time Charter Equivalent (“TCE”) rate is a non-GAAP measure. Please see the reconciliation below of TCE rate to Net Revenues from vessels, the most directly comparable U.S. GAAP measure.

GLYFADA, Greece, Nov. 12, 2026 (GLOBE NEWSWIRE) — United Maritime Corporation (“United” or the “Company”) (NASDAQ: USEA) announced today its financial results for the third quarter and nine months ended September 30, 2026. The Company also declared a quarterly dividend of $0.20 per common share for the third quarter of 2026.

For the quarter ended September 30, 2026, the Company generated Net Revenues of $12.0 million, compared to $11.0 million in the prior-year period, despite fewer ownership days resulting from its ongoing fleet repositioning strategy. Net Income and Adjusted Net Income for the quarter were $3.2 million and $4.0 million, respectively, compared to $1.1 million and $1.6 million, respectively, in the third quarter of 2025. Adjusted EBITDA for the quarter was $8.0 million, compared to $5.4 million for the same period of 2025. Fleet TCE increased 37% year-over-year to $20,737 per day, driven by stronger dry bulk market conditions and the increased earnings contribution of the Company’s Capesize vessels.

For the first nine months of 2026, the Company generated Net Revenues of $29.9 million and Adjusted EBITDA of $16.4 million, compared to $31.2 million and $11.4 million, respectively, in the same period of 2025. Net Income and Adjusted Net Income for the period were $4.2 million and $5.7 million, respectively, compared to Net Loss of $2.4 million and Adjusted Net Loss of $2.6 million in the respective period of 2025. Fleet TCE increased 37% to $18,446 per day year-over-year. The average daily OPEX was $6,607 compared to $6,323 for the same period of 2025, reflecting the higher share of Capesize vessels in the fleet.

As of September 30, 2026, United held $24.4 million in cash, cash equivalents and restricted cash, with shareholders’ equity standing at $56.1 million, while bank debt, finance lease liabilities and other financial liabilities, net of deferred finance costs stood at $83.7 million. Total debt declined by $10.5 million during the quarter, primarily due to the repayment of the debt associated with the M/V Exelixsea. The book value of the Company’s fleet as of September 30, 2026, stood at $126.2 million, reflecting the Company’s strategic expansion into the Capesize segment.

Stamatis Tsantanis, the Company’s Chairman & Chief Executive Officer, stated:

“Our capital reallocation is beginning to generate meaningful returns: third-quarter Net Income tripled to $3.2 million and Adjusted EBITDA rose 48% to $8.0 million. Our fleet earned $20,737 per day – up 37% year-over-year, 11% above the second quarter and ahead of our guidance. We are now beginning to see the operating leverage benefits of our Capesize-weighted fleet.

Our board has declared a quarterly dividend of $0.20 per share – double the dividend declared for the second quarter. This represents the Company’s 16th consecutive quarterly cash distribution. With our two operating Capesizes fixed for 2027, contracted cash flows support this dividend.

Our third Capesize, the 2009-built M/V Friendship, is expected to be delivered in early Q1 2027, funded with debt and the proceeds of our recent asset sales. Capesizes will then represent approximately 69% of our fleet’s carrying capacity. Our strategy remains unchanged: divest lower-performing assets and redeploy capital into higher-earning assets that generate stronger results for our shareholders.

Four of our five vessels are fixed for the fourth quarter, and we expect a Q4 TCE of approximately $22,689 per day, representing a further 10% increase. More importantly, our two operating Capesizes are now fixed for the whole of 2027 – the M/V Dukeship at over $35,000 per day and the M/V Squireship at over $29,100 per day. Together, these charters represent approximately $23.1 million of contracted gross hire from two vessels, while the remainder of our fleet retains exposure to potential upside in the market.

The dry bulk sector performed very strongly in the third quarter, driven mainly by record bauxite volumes and continued ton-mile growth in iron ore, while grain and coal volumes have also remained supportive throughout the year. On the supply side, vessel routing inefficiencies, including those associated with the Panama Canal, and ongoing geopolitical disruptions have kept effective fleet growth limited. Looking ahead, market fundamentals remain constructive, with a relatively modest orderbook set against a rapidly aging fleet, which we believe should continue to support freight rates.

Our priorities are clear: build on the earnings gains achieved to date, continue reallocating capital into higher-earning assets, and convert stronger performance into sustainable cash distributions. United is well positioned to deliver on all three.”

_______________
³ The amounts include the 16th consecutive quarterly cash dividend declared but not yet paid.

Company Fleet:

Vessel Name	Sector	Capacity (DWT)	Year Built	Yard	Employment Type	Minimum T/C expiration	Maximum T/C expiration(1)
Dukeship(2)	Capesize	181,453	2010	Sasebo	T/C Index Linked(3)	Jan-28	Mar-28
Squireship	Capesize	170,018	2010	Sungdong	T/C Index Linked(3)	Jan-28	Mar-28
Nisea	Kamsarmax	82,235	2016	Oshima	T/C Index Linked(3)	Jul-27	Sep-27
Chrisea	Panamax	78,173	2013	Shin Kurushima	T/C Index Linked(3)	Mar-27	Jul-27
Synthesea	Panamax	78,020	2015	Sasebo	T/C Index Linked(3)	Jan-28	Apr-28
Total/Average age		589,899	13.8 years
Vessel to be delivered
Friendship(4)	Capesize	176,952	2009	Namura	T/C Index Linked(3)	Apr-27	Sep-27

(1) The latest redelivery dates do not include any additional optional periods.

(2) The vessel is technically and commercially operated by the Company on the basis of an 18-month bareboat charter-in contract with the owners of the vessel, including a purchase obligation at the end of the bareboat charter.

(3) “T/C” refers to a time charter agreement. Under these index-linked T/Cs, the Company has the option to convert the index-linked rate to fixed for a minimum period of two months, based on the prevailing FFA Rates for the selected period, and has done so for certain vessels as part of its freight hedging strategy, as described below under “Fourth Quarter 2026 TCE Rate Guidance”.

(4) The vessel is expected to be delivered in early Q1 2027.

Fleet Data:

	Q3 2026			Q3 2025			9M 2026			9M 2025
Ownership days (1)		547			583			1,570			2,010
Operating days (2)		543			578			1,543			1,963
Fleet utilization (3)		99.3	%		99.1	%		98.3	%		97.7	%
TCE rate (4)	$	20,737		$	15,093		$	18,446		$	13,436
Daily Vessel Operating Expenses (5)	$	6,916		$	6,300		$	6,607		$	6,323

(1) Ownership days are the total number of calendar days in a period during which the vessels in a fleet have been owned or chartered. Ownership days are an indicator of the size of the Company’s fleet over a period and affect both the amount of revenues and the amount of expenses that the Company recorded during a period.

(2) Operating days are the number of available days in a period less the aggregate number of days that the vessels are off-hire due to unforeseen circumstances. Available days are the number of ownership days less the aggregate number of days that our vessels are off-hire due to major repairs, dry-dockings, lay-up or special or intermediate surveys. Operating days include the days that our vessels are on ballast voyages without having finalized agreements for their next employment. The Company’s calculation of operating days may not be comparable to that reported by other companies.

(3) Fleet utilization is the percentage of time that the vessels are generating revenue and is determined by dividing operating days by ownership days for the relevant period.

(4) TCE rate is defined as the Company’s net revenue less voyage expenses during a period divided by the number of the Company’s operating days during the period. Voyage expenses include port charges, bunker (fuel oil and diesel oil) expenses, canal charges and other commissions. The Company includes the TCE rate, a non-GAAP measure, as it believes it provides additional meaningful information in conjunction with net revenues from vessels, the most directly comparable U.S. GAAP measure, and because it assists the Company’s management in making decisions regarding the deployment and use of our vessels and because the Company believes that it provides useful information to investors regarding our financial performance. The Company’s calculation of TCE rate may not be comparable to that reported by other companies. The following table reconciles the Company’s net revenues from vessels to the TCE rate.

(In thousands of U.S. Dollars, except operating days and TCE rate)

	Q3 2026		Q3 2025		9M 2026		9M 2025
Vessel revenue, net		11,970		10,966		29,907		31,193
Less: Voyage expenses		710		2,242		1,445		4,818
Time charter equivalent revenues		11,260		8,724		28,462		26,375
Operating days		543		578		1,543		1,963
TCE rate	$	20,737	$	15,093	$	18,446	$	13,436

(5) Vessel operating expenses include crew costs, provisions, deck and engine stores, lubricants, insurance, maintenance and repairs. Daily Vessel Operating Expenses are calculated by dividing vessel operating expenses, excluding pre-delivery costs of acquired vessels, if applicable, by ownership days for the relevant time periods. The Company’s calculation of daily vessel operating expenses may not be comparable to that reported by other companies. The following table reconciles the Company’s vessel operating expenses to daily vessel operating expenses.

(In thousands of U.S. Dollars, except ownership days and Daily Vessel Operating Expenses) 

	Q3 2026		Q3 2025		9M 2026		9M 2025
Vessel operating expenses		3,783		3,673		10,373		12,709
Ownership days		547		583		1,570		2,010
Daily Vessel Operating Expenses	$	6,916	$	6,300	$	6,607	$	6,323

Net Income / (Loss) to EBITDA and Adjusted EBITDA Reconciliation:

(In thousands of U.S. Dollars)

	Q3 2026	Q3 2025	9M 2026	9M 2025
Net income / (loss)	3,219	1,066	4,240	(2,441	)
Interest and finance costs, net	1,304	1,429	3,730	5,129
Depreciation and amortization	2,703	2,377	6,986	8,817
EBITDA	7,226	4,872	14,956	11,505
Stock based compensation	205	118	796	427
Loss on extinguishment of debt	495	407	608	640
Loss on liquidation of subsidiary	58	–	58	–
Loss on forward freight agreements	6	–	6	–
Gain on consolidation	–	–	–	(1,268	)
Loss on equity method investment	–	6	7	50
Adjusted EBITDA	7,990	5,403	16,431	11,354

Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) represents the sum of net income, net interest and finance costs, depreciation and amortization and, if any, income taxes during a period. EBITDA and Adjusted EBITDA are not recognized measurements under U.S. GAAP. Adjusted EBITDA represents EBITDA adjusted to exclude stock-based compensation, loss on extinguishment of debt, loss on liquidation of subsidiary, loss on forward freight agreements, gain on consolidation and loss on equity method investment, which the Company believes are not indicative of the ongoing performance of its core operations.

EBITDA and Adjusted EBITDA are presented as we believe that these measures are useful to investors as a widely used means of evaluating operating profitability. EBITDA and Adjusted EBITDA as presented here may not be comparable to similarly titled measures presented by other companies. These non-GAAP measures should not be considered in isolation from, as a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP.

Net Income / (Loss) and Adjusted Net Income / (Loss) Reconciliation and calculation of Adjusted Earnings / (Loss) Per Share

(In thousands of U.S. Dollars)

	Q3 2026	Q3 2025	9M 2026	9M 2025
Net income / (loss)	3,219	1,066	4,240	(2,441	)
Stock based compensation	205	118	796	427
Loss on extinguishment of debt	495	407	608	640
Gain on consolidation	–	–	–	(1,268	)
Loss on equity method investment	–	6	7	50
Loss on forward freight agreements	6	–	6	–
Loss on liquidation of subsidiary	58	–	58	–
Adjusted net income / (loss)	3,983	1,597	5,715	(2,592	)
Adjusted net income / (loss) – common stockholders, basic	3,944	1,597	5,644	(2,563	)
Adjusted net income / (loss) – common stockholders, diluted	3,944	1,597	5,734	(2,563	)
Adjusted earnings / (loss) per common share, basic	0.43	0.18	0.62	(0.29	)
Adjusted earnings / (loss) per common share, diluted	0.38	0.18	0.58	(0.29	)
Weighted average number of common shares outstanding, basic	9,241,792	8,917,144	9,121,465	8,841,632
Weighted average number of common shares outstanding, diluted	10,406,256	8,917,144	9,834,583	8,841,632

To derive Adjusted Net Income / (Loss) and Adjusted Earnings / (Loss) Per Share, both non-GAAP measures, from Net income / (Loss), we exclude certain non-cash items, as provided in the table above. We believe that Adjusted Net Income / (Loss) and Earnings / (Loss) Per Share assist our management and investors by increasing the comparability of our performance from period to period since each such measure eliminates the effects of such non-cash items as stock-based compensation, loss on extinguishment of debt, gain on consolidation, loss on equity method investment, loss on forward freight agreements, loss on liquidation of subsidiary and other items which may vary from year to year, for reasons unrelated to overall operating performance. In addition, we believe that the presentation of the respective measures provides investors with supplemental data relating to our results of operations, and therefore, with a more complete understanding of factors affecting our business than with GAAP measures alone. Our method of computing Adjusted Net Income / (Loss) and Adjusted Earnings / (Loss) Per Share may not necessarily be comparable to other similarly titled captions of other companies due to differences in methods of calculation.

Fourth Quarter 2026 TCE Rate Guidance:

As of the date hereof, approximately 88% of the Company fleet’s expected operating days in the fourth quarter of 2026 have been fixed at an estimated TCE rate of approximately $23,339 per day. Assuming that for the remaining operating days of our index-linked T/Cs, the BPI-82 rate will be equal to an average of $19,029 per day (based on the FFA curve of November 5, 2026), our estimated TCE for the fourth quarter of 2026 is approximately $22,689⁴ per day. Our TCE rate guidance for the fourth quarter of 2026 includes the already performed conversions of index-linked charters to fixed for the period.

The following table provides the breakdown of index-linked charters and fixed-rate charters in the fourth quarter of 2026:

	Operating Days	TCE Rate
TCE – fixed rate (including index-linked conversions)	365	$	23,715
TCE – index-linked	92	$	18,624
Total / Average	457	$	22,689

Third Quarter and Recent Developments:

Dividend Distribution for Q2 2026 and Declaration of Q3 2026 Dividend

On October 9, 2026, the Company paid a quarterly dividend of $0.10 per common share, for the second quarter of 2026, to all shareholders of record as of September 25, 2026.

The Company has declared a quarterly cash dividend of $0.20 per common share for the third quarter of 2026 payable on or about January 8, 2027, to all shareholders of record as of December 24, 2026.

Vessel transactions and commercial updates

Sale of M/V Exelixsea

In September 2026, the Company delivered the 76,361 dwt M/V Exelixsea, built in 2011, to her new owners. The vessel was sold for a gross consideration of approximately $17.5 million, generating net cash proceeds of approximately $8.7 million following repayment of the associated debt. In addition, the transaction resulted in a gain on sale of approximately $1.8 million, which was recognized in the third quarter of 2026.

Acquisition of M/V Friendship

In November 2026, the Company agreed main terms with Seanergy Maritime Holdings Corp. (“Seanergy”), for the acquisition of the 2009-built Capesize bulk carrier M/V Friendship, constructed in Japan, for an aggregate purchase price of $33.0 million. A special independent and disinterested committee of the Company’s board of directors negotiated and approved the terms. The acquisition remains subject to the existing financier’s approval and parties entering into final documentation. The vessel is expected to be delivered to the Company in early Q1 2027. The acquisition is expected to be financed through a combination of debt financing and proceeds generated from recent asset monetization initiatives.

M/V Dukeship – Time charter extension

In August 2026, the charterer of the M/V Dukeship agreed to an extension of the time charter agreement, providing for a new redelivery window from January 2028 to March 2028. The daily hire is based on the 5 T/C routes of the BCI, and all other main terms of the time charter remain materially unchanged.

M/V Squireship – Time charter extension

In September 2026, the charterer of the M/V Squireship agreed to extend the time charter agreement in direct continuation from the previous agreement. The extension period will commence in January 2027, for a minimum of January 2028 and a maximum of March 2028. The daily hire is based on the 5 T/C routes of the BCI, and all other main terms of the time charter remain materially unchanged.

M/Vs Dukeship and Squireship – Hire Conversions  

In September 2026, the Company converted the M/V Dukeship’s charter hire to a fixed daily gross rate exceeding $35,000 for 2027.

In November 2026, the Company converted the M/V Squireship’s charter hire to a fixed daily gross rate exceeding $29,100 for 2027.

Financing Updates

M/V Dukeship – Financing

In November 2026, the Company agreed main terms with a Japanese counterparty for a sale and leaseback agreement to fully finance the purchase obligation under the current bareboat charter of the M/V Dukeship, well in advance of its due date in the third quarter of 2027. The transaction remains subject to credit committee approval and definite documentation.

_______________
⁴ This guidance is based on certain assumptions, and the Company cannot provide assurance that these TCE rate estimates or projected utilization rates will be realized. TCE estimates include certain floating (index) to fixed rate conversions concluded in previous periods. For vessels on index-linked T/Cs, the TCE rate realized will vary with the underlying index, and for the purposes of this guidance, the BPI-82 rate assumed for the remaining operating days of the quarter for an index-linked T/C is equal to an average of $19,029 per day (based on the FFA curve as of November 5, 2026). Spot estimates are provided using the load-to-discharge method of accounting. The rates quoted are for days currently contracted. Increased ballast days at the end of the quarter will reduce the additional revenues that can be booked based on the accounting cut-offs and therefore the resulting TCE rate will be reduced accordingly.

United Maritime Corporation Unaudited Condensed Consolidated Balance Sheets (In thousands of U.S. Dollars)
		September 30, 2026			December 31, 2025*
ASSETS
Cash and cash equivalents and restricted cash		24,410			14,564
Vessels, net, Right-of-use assets and Vessel held for sale		126,206			99,885
Other assets		6,531			24,232
TOTAL ASSETS		157,147			138,681
LIABILITIES AND STOCKHOLDERS’ EQUITY
Long-term debt, finance lease liability and other financial liabilities, net of deferred finance costs		83,736			64,839
Other liabilities		17,287			17,376
Stockholders’ equity		56,124			56,466
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		157,147			138,681

* Derived from the audited consolidated financial statements as of the period as of that date

United Maritime Corporation Unaudited Condensed Consolidated Statements of Operations (In thousands of U.S. Dollars, except for share and per share data)
		Three months ended September 30,				Nine months ended September 30,
		2026		2025		2026			2025
Vessel revenue, net		11,970		10,966		29,907			31,193
Expenses:
Voyage expenses		(710	)	(2,242	)	(1,445	)		(4,818	)
Vessel operating expenses		(3,783	)	(3,673	)	(10,373	)		(12,709	)
Management fees		(456	)	(477	)	(1,311	)		(1,652	)
General and administration expenses		(1,111	)	(1,196	)	(3,740	)		(2,628	)
Depreciation and amortization		(2,703	)	(2,377	)	(6,986	)		(8,817	)
Loss on forward freight agreements		(6	)	–		(6	)		–
Gain on disposal of equity method investment		–		–		523			–
Gain on sale of vessels		1,811		1,928		1,967			1,773
Operating income		5,012		2,929		8,536			2,342
Other income / (expenses):
Interest and finance costs		(1,159	)	(1,494	)	(3,401	)		(5,186	)
Interest and finance costs – related party		(182	)	–		(464	)		(48	)
Interest income		36		65		135			105
Loss on extinguishment of debt		(495	)	(407	)	(608	)		(640	)
Gain on consolidation		–		–		–			1,268
Loss on liquidation of subsidiary		(58	)	–		(58	)		–
Loss on equity method investment		–		(6	)	(7	)		(50	)
Other income		15		–		63			–
Other, net		50		(21	)	44			(232	)
Total other expenses, net:		(1,793	)	(1,863	)	(4,296	)		(4,783	)
Net income / (loss)		3,219		1,066		4,240			(2,441	)
Net income / (loss) attributable to common shareholders, basic		3,180		1,066		4,169			(2,412	)
Net income / (loss) attributable to common shareholders, diluted		3,180		1,066		4,259			(2,412	)
Earnings / (loss) per common share, basic		0.34		0.12		0.46			(0.27	)
Earnings / (loss) per common shares, diluted		0.31		0.12		0.43			(0.27	)
Weighted average number of common shares outstanding, basic		9,241,792		8,917,144		9,121,465			8,841,632
Weighted average number of common shares outstanding, diluted		10,406,256		8,917,144		9,834,583			8,841,632

United Maritime Corporation Unaudited Condensed Consolidated Cash Flow Data (In thousands of U.S. Dollars)
		Nine months ended September 30,
		2026		2025
Net cash provided by / (used in) operating activities		9,959		(44	)
Net cash provided by investing activities		31,101		45,737
Net cash used in financing activities		(31,130	)	(32,333	)

About United Maritime Corporation

United Maritime Corporation is an international shipping company specializing in worldwide seaborne transportation services. The Company operates a fleet of five dry bulk vessels, comprising two Capesize, one Kamsarmax and two Panamax vessels, with an aggregate cargo carrying capacity of 589,899 dwt. Upon completion of the aforementioned acquisition of the M/V Friendship, the Company’s operating fleet will consist of six vessels (three Capesize, one Kamsarmax and two Panamax vessels), with an aggregate cargo carrying capacity of 766,851 dwt.

The Company is incorporated under the laws of the Republic of the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “USEA”.

Please visit the Company’s website at: www.unitedmaritime.gr.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, including with respect to declaration of dividends, market trends and cash distributions. Words such as “may”, “should”, “expects”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s operating or financial results; the Company’s liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, impacts of litigation, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations outside the United States; risks arising from trade disputes between the U.S. and China, including the re-imposition of reciprocal port fees; broader market impacts arising from trade disputes or war (or threatened war) or international hostilities, such as between the U.S. and Israel and Iran, the U.S. and Venezuela, China and Taiwan, and Russia and Ukraine; risks associated with the length and severity of pandemics; and other factors listed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its most recent annual report on Form 20-F. The Company’s filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information please contact:

United Investor Relations
Tel: +30 213 0181 522
E-mail: ir@usea.gr

Capital Link, Inc.
Paul Lampoutis
230 Park Avenue Suite 1540
New York, NY 10169
Tel: +1 212 661 7566
E-mail: usea@capitallink.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a4bd94b7-a49d-4554-83dc-59ec22ba3cb6

Quarterly Net Income Triples to $3.2 Million as Capital Reallocation Lifts Fleet TCE 37%

Further Expands Capesize Fleet; Fixes M/V Dukeship and M/V Squireship for 2027 at Attractive Charter Rates

Highlights (in million USD, except EPS, LPS and TCE)	Q3 2026		Q3 2025		9M 2026		9M 2025			9M 2026 vs 9M 2025
Net Revenues	$	12.0	$	11.0	$	29.9	$	31.2
Net Income / (Loss)	$	3.2	$	1.1	$	4.2	$	(2.4	)
Adjusted Net Income / (Loss)1	$	4.0	$	1.6	$	5.7	$	(2.6	)
EBITDA1	$	7.2	$	4.9	$	15.0	$	11.5		+30	%
Adjusted EBITDA1	$	8.0	$	5.4	$	16.4	$	11.4		+45	%
TCE2	$	20,737	$	15,093	$	18,446	$	13,436		+37	%
Earnings / (Loss) per share Basic	$	0.34	$	0.12	$	0.46	$	(0.27	)
Earnings / (Loss) per share Diluted	$	0.31	$	0.12	$	0.43	$	(0.27	)
Adjusted Earnings / (Loss) per share Basic1	$	0.43	$	0.18	$	0.62	$	(0.29	)
Adjusted Earnings / (Loss) per share Diluted1	$	0.38	$	0.18	$	0.58	$	(0.29	)

Other Highlights and Developments:

• Strong Third Quarter Financial Performance Reflecting Benefits of Strategic Fleet Repositioning
  • Quarterly Net Income of $3.2 million and Adjusted EBITDA of $8.0 million, with fleet TCE increasing 37% year-over-year to $20,737 per day.
  • Nine-month Adjusted EBITDA increased 45% to $16.4 million, with fleet TCE up 37% to $18,446 per day.
• Cash Dividend for the Third Quarter Doubled to $0.20 Per Share
  • 16^th consecutive quarterly dividend, bringing cumulative cash distributions since November 2022 to $2.24 per share, or approximately $18.7 million.³
• Continued Capital Reallocation Through Further Capesize Expansion
  • Agreed to acquire the 2009-built Capesize vessel M/V Friendship, with delivery expected in early Q1 2027.
  • Completed the sale of the 2011-built Panamax M/V Exelixsea, generating $8.7 million of net cash proceeds and a gain of $1.8 million.

_______________
¹ Adjusted Earnings / (Loss) per share, Adjusted Net Income / (Loss), EBITDA and Adjusted EBITDA are non-GAAP measures. Please see the reconciliation below of Adjusted Earnings / (Loss) per share, Adjusted Net Income / (loss), EBITDA and Adjusted EBITDA to Net Income / (Loss), the most directly comparable U.S. GAAP measure.
² Time Charter Equivalent (“TCE”) rate is a non-GAAP measure. Please see the reconciliation below of TCE rate to Net Revenues from vessels, the most directly comparable U.S. GAAP measure.

GLYFADA, Greece, Nov. 12, 2026 (GLOBE NEWSWIRE) — United Maritime Corporation (“United” or the “Company”) (NASDAQ: USEA) announced today its financial results for the third quarter and nine months ended September 30, 2026. The Company also declared a quarterly dividend of $0.20 per common share for the third quarter of 2026.

For the quarter ended September 30, 2026, the Company generated Net Revenues of $12.0 million, compared to $11.0 million in the prior-year period, despite fewer ownership days resulting from its ongoing fleet repositioning strategy. Net Income and Adjusted Net Income for the quarter were $3.2 million and $4.0 million, respectively, compared to $1.1 million and $1.6 million, respectively, in the third quarter of 2025. Adjusted EBITDA for the quarter was $8.0 million, compared to $5.4 million for the same period of 2025. Fleet TCE increased 37% year-over-year to $20,737 per day, driven by stronger dry bulk market conditions and the increased earnings contribution of the Company’s Capesize vessels.

For the first nine months of 2026, the Company generated Net Revenues of $29.9 million and Adjusted EBITDA of $16.4 million, compared to $31.2 million and $11.4 million, respectively, in the same period of 2025. Net Income and Adjusted Net Income for the period were $4.2 million and $5.7 million, respectively, compared to Net Loss of $2.4 million and Adjusted Net Loss of $2.6 million in the respective period of 2025. Fleet TCE increased 37% to $18,446 per day year-over-year. The average daily OPEX was $6,607 compared to $6,323 for the same period of 2025, reflecting the higher share of Capesize vessels in the fleet.

As of September 30, 2026, United held $24.4 million in cash, cash equivalents and restricted cash, with shareholders’ equity standing at $56.1 million, while bank debt, finance lease liabilities and other financial liabilities, net of deferred finance costs stood at $83.7 million. Total debt declined by $10.5 million during the quarter, primarily due to the repayment of the debt associated with the M/V Exelixsea. The book value of the Company’s fleet as of September 30, 2026, stood at $126.2 million, reflecting the Company’s strategic expansion into the Capesize segment.

Stamatis Tsantanis, the Company’s Chairman & Chief Executive Officer, stated:

“Our capital reallocation is beginning to generate meaningful returns: third-quarter Net Income tripled to $3.2 million and Adjusted EBITDA rose 48% to $8.0 million. Our fleet earned $20,737 per day – up 37% year-over-year, 11% above the second quarter and ahead of our guidance. We are now beginning to see the operating leverage benefits of our Capesize-weighted fleet.

Our board has declared a quarterly dividend of $0.20 per share – double the dividend declared for the second quarter. This represents the Company’s 16th consecutive quarterly cash distribution. With our two operating Capesizes fixed for 2027, contracted cash flows support this dividend.

Our third Capesize, the 2009-built M/V Friendship, is expected to be delivered in early Q1 2027, funded with debt and the proceeds of our recent asset sales. Capesizes will then represent approximately 69% of our fleet’s carrying capacity. Our strategy remains unchanged: divest lower-performing assets and redeploy capital into higher-earning assets that generate stronger results for our shareholders.

Four of our five vessels are fixed for the fourth quarter, and we expect a Q4 TCE of approximately $22,689 per day, representing a further 10% increase. More importantly, our two operating Capesizes are now fixed for the whole of 2027 – the M/V Dukeship at over $35,000 per day and the M/V Squireship at over $29,100 per day. Together, these charters represent approximately $23.1 million of contracted gross hire from two vessels, while the remainder of our fleet retains exposure to potential upside in the market.

The dry bulk sector performed very strongly in the third quarter, driven mainly by record bauxite volumes and continued ton-mile growth in iron ore, while grain and coal volumes have also remained supportive throughout the year. On the supply side, vessel routing inefficiencies, including those associated with the Panama Canal, and ongoing geopolitical disruptions have kept effective fleet growth limited. Looking ahead, market fundamentals remain constructive, with a relatively modest orderbook set against a rapidly aging fleet, which we believe should continue to support freight rates.

Our priorities are clear: build on the earnings gains achieved to date, continue reallocating capital into higher-earning assets, and convert stronger performance into sustainable cash distributions. United is well positioned to deliver on all three.”

_______________
³ The amounts include the 16th consecutive quarterly cash dividend declared but not yet paid.

Company Fleet:

Vessel Name	Sector	Capacity (DWT)	Year Built	Yard	Employment Type	Minimum T/C expiration	Maximum T/C expiration(1)
Dukeship(2)	Capesize	181,453	2010	Sasebo	T/C Index Linked(3)	Jan-28	Mar-28
Squireship	Capesize	170,018	2010	Sungdong	T/C Index Linked(3)	Jan-28	Mar-28
Nisea	Kamsarmax	82,235	2016	Oshima	T/C Index Linked(3)	Jul-27	Sep-27
Chrisea	Panamax	78,173	2013	Shin Kurushima	T/C Index Linked(3)	Mar-27	Jul-27
Synthesea	Panamax	78,020	2015	Sasebo	T/C Index Linked(3)	Jan-28	Apr-28
Total/Average age		589,899	13.8 years
Vessel to be delivered
Friendship(4)	Capesize	176,952	2009	Namura	T/C Index Linked(3)	Apr-27	Sep-27

(1) The latest redelivery dates do not include any additional optional periods.

(2) The vessel is technically and commercially operated by the Company on the basis of an 18-month bareboat charter-in contract with the owners of the vessel, including a purchase obligation at the end of the bareboat charter.

(3) “T/C” refers to a time charter agreement. Under these index-linked T/Cs, the Company has the option to convert the index-linked rate to fixed for a minimum period of two months, based on the prevailing FFA Rates for the selected period, and has done so for certain vessels as part of its freight hedging strategy, as described below under “Fourth Quarter 2026 TCE Rate Guidance”.

(4) The vessel is expected to be delivered in early Q1 2027.

Fleet Data:

	Q3 2026			Q3 2025			9M 2026			9M 2025
Ownership days (1)		547			583			1,570			2,010
Operating days (2)		543			578			1,543			1,963
Fleet utilization (3)		99.3	%		99.1	%		98.3	%		97.7	%
TCE rate (4)	$	20,737		$	15,093		$	18,446		$	13,436
Daily Vessel Operating Expenses (5)	$	6,916		$	6,300		$	6,607		$	6,323

(1) Ownership days are the total number of calendar days in a period during which the vessels in a fleet have been owned or chartered. Ownership days are an indicator of the size of the Company’s fleet over a period and affect both the amount of revenues and the amount of expenses that the Company recorded during a period.

(2) Operating days are the number of available days in a period less the aggregate number of days that the vessels are off-hire due to unforeseen circumstances. Available days are the number of ownership days less the aggregate number of days that our vessels are off-hire due to major repairs, dry-dockings, lay-up or special or intermediate surveys. Operating days include the days that our vessels are on ballast voyages without having finalized agreements for their next employment. The Company’s calculation of operating days may not be comparable to that reported by other companies.

(3) Fleet utilization is the percentage of time that the vessels are generating revenue and is determined by dividing operating days by ownership days for the relevant period.

(4) TCE rate is defined as the Company’s net revenue less voyage expenses during a period divided by the number of the Company’s operating days during the period. Voyage expenses include port charges, bunker (fuel oil and diesel oil) expenses, canal charges and other commissions. The Company includes the TCE rate, a non-GAAP measure, as it believes it provides additional meaningful information in conjunction with net revenues from vessels, the most directly comparable U.S. GAAP measure, and because it assists the Company’s management in making decisions regarding the deployment and use of our vessels and because the Company believes that it provides useful information to investors regarding our financial performance. The Company’s calculation of TCE rate may not be comparable to that reported by other companies. The following table reconciles the Company’s net revenues from vessels to the TCE rate.

(In thousands of U.S. Dollars, except operating days and TCE rate)

	Q3 2026		Q3 2025		9M 2026		9M 2025
Vessel revenue, net		11,970		10,966		29,907		31,193
Less: Voyage expenses		710		2,242		1,445		4,818
Time charter equivalent revenues		11,260		8,724		28,462		26,375
Operating days		543		578		1,543		1,963
TCE rate	$	20,737	$	15,093	$	18,446	$	13,436

(5) Vessel operating expenses include crew costs, provisions, deck and engine stores, lubricants, insurance, maintenance and repairs. Daily Vessel Operating Expenses are calculated by dividing vessel operating expenses, excluding pre-delivery costs of acquired vessels, if applicable, by ownership days for the relevant time periods. The Company’s calculation of daily vessel operating expenses may not be comparable to that reported by other companies. The following table reconciles the Company’s vessel operating expenses to daily vessel operating expenses.

(In thousands of U.S. Dollars, except ownership days and Daily Vessel Operating Expenses) 

	Q3 2026		Q3 2025		9M 2026		9M 2025
Vessel operating expenses		3,783		3,673		10,373		12,709
Ownership days		547		583		1,570		2,010
Daily Vessel Operating Expenses	$	6,916	$	6,300	$	6,607	$	6,323

Net Income / (Loss) to EBITDA and Adjusted EBITDA Reconciliation:

(In thousands of U.S. Dollars)

	Q3 2026	Q3 2025	9M 2026	9M 2025
Net income / (loss)	3,219	1,066	4,240	(2,441	)
Interest and finance costs, net	1,304	1,429	3,730	5,129
Depreciation and amortization	2,703	2,377	6,986	8,817
EBITDA	7,226	4,872	14,956	11,505
Stock based compensation	205	118	796	427
Loss on extinguishment of debt	495	407	608	640
Loss on liquidation of subsidiary	58	–	58	–
Loss on forward freight agreements	6	–	6	–
Gain on consolidation	–	–	–	(1,268	)
Loss on equity method investment	–	6	7	50
Adjusted EBITDA	7,990	5,403	16,431	11,354

Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) represents the sum of net income, net interest and finance costs, depreciation and amortization and, if any, income taxes during a period. EBITDA and Adjusted EBITDA are not recognized measurements under U.S. GAAP. Adjusted EBITDA represents EBITDA adjusted to exclude stock-based compensation, loss on extinguishment of debt, loss on liquidation of subsidiary, loss on forward freight agreements, gain on consolidation and loss on equity method investment, which the Company believes are not indicative of the ongoing performance of its core operations.

EBITDA and Adjusted EBITDA are presented as we believe that these measures are useful to investors as a widely used means of evaluating operating profitability. EBITDA and Adjusted EBITDA as presented here may not be comparable to similarly titled measures presented by other companies. These non-GAAP measures should not be considered in isolation from, as a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP.

Net Income / (Loss) and Adjusted Net Income / (Loss) Reconciliation and calculation of Adjusted Earnings / (Loss) Per Share

(In thousands of U.S. Dollars)

	Q3 2026	Q3 2025	9M 2026	9M 2025
Net income / (loss)	3,219	1,066	4,240	(2,441	)
Stock based compensation	205	118	796	427
Loss on extinguishment of debt	495	407	608	640
Gain on consolidation	–	–	–	(1,268	)
Loss on equity method investment	–	6	7	50
Loss on forward freight agreements	6	–	6	–
Loss on liquidation of subsidiary	58	–	58	–
Adjusted net income / (loss)	3,983	1,597	5,715	(2,592	)
Adjusted net income / (loss) – common stockholders, basic	3,944	1,597	5,644	(2,563	)
Adjusted net income / (loss) – common stockholders, diluted	3,944	1,597	5,734	(2,563	)
Adjusted earnings / (loss) per common share, basic	0.43	0.18	0.62	(0.29	)
Adjusted earnings / (loss) per common share, diluted	0.38	0.18	0.58	(0.29	)
Weighted average number of common shares outstanding, basic	9,241,792	8,917,144	9,121,465	8,841,632
Weighted average number of common shares outstanding, diluted	10,406,256	8,917,144	9,834,583	8,841,632

To derive Adjusted Net Income / (Loss) and Adjusted Earnings / (Loss) Per Share, both non-GAAP measures, from Net income / (Loss), we exclude certain non-cash items, as provided in the table above. We believe that Adjusted Net Income / (Loss) and Earnings / (Loss) Per Share assist our management and investors by increasing the comparability of our performance from period to period since each such measure eliminates the effects of such non-cash items as stock-based compensation, loss on extinguishment of debt, gain on consolidation, loss on equity method investment, loss on forward freight agreements, loss on liquidation of subsidiary and other items which may vary from year to year, for reasons unrelated to overall operating performance. In addition, we believe that the presentation of the respective measures provides investors with supplemental data relating to our results of operations, and therefore, with a more complete understanding of factors affecting our business than with GAAP measures alone. Our method of computing Adjusted Net Income / (Loss) and Adjusted Earnings / (Loss) Per Share may not necessarily be comparable to other similarly titled captions of other companies due to differences in methods of calculation.

Fourth Quarter 2026 TCE Rate Guidance:

As of the date hereof, approximately 88% of the Company fleet’s expected operating days in the fourth quarter of 2026 have been fixed at an estimated TCE rate of approximately $23,339 per day. Assuming that for the remaining operating days of our index-linked T/Cs, the BPI-82 rate will be equal to an average of $19,029 per day (based on the FFA curve of November 5, 2026), our estimated TCE for the fourth quarter of 2026 is approximately $22,689⁴ per day. Our TCE rate guidance for the fourth quarter of 2026 includes the already performed conversions of index-linked charters to fixed for the period.

The following table provides the breakdown of index-linked charters and fixed-rate charters in the fourth quarter of 2026:

	Operating Days	TCE Rate
TCE – fixed rate (including index-linked conversions)	365	$	23,715
TCE – index-linked	92	$	18,624
Total / Average	457	$	22,689

Third Quarter and Recent Developments:

Dividend Distribution for Q2 2026 and Declaration of Q3 2026 Dividend

On October 9, 2026, the Company paid a quarterly dividend of $0.10 per common share, for the second quarter of 2026, to all shareholders of record as of September 25, 2026.

The Company has declared a quarterly cash dividend of $0.20 per common share for the third quarter of 2026 payable on or about January 8, 2027, to all shareholders of record as of December 24, 2026.

Vessel transactions and commercial updates

Sale of M/V Exelixsea

In September 2026, the Company delivered the 76,361 dwt M/V Exelixsea, built in 2011, to her new owners. The vessel was sold for a gross consideration of approximately $17.5 million, generating net cash proceeds of approximately $8.7 million following repayment of the associated debt. In addition, the transaction resulted in a gain on sale of approximately $1.8 million, which was recognized in the third quarter of 2026.

Acquisition of M/V Friendship

In November 2026, the Company agreed main terms with Seanergy Maritime Holdings Corp. (“Seanergy”), for the acquisition of the 2009-built Capesize bulk carrier M/V Friendship, constructed in Japan, for an aggregate purchase price of $33.0 million. A special independent and disinterested committee of the Company’s board of directors negotiated and approved the terms. The acquisition remains subject to the existing financier’s approval and parties entering into final documentation. The vessel is expected to be delivered to the Company in early Q1 2027. The acquisition is expected to be financed through a combination of debt financing and proceeds generated from recent asset monetization initiatives.

M/V Dukeship – Time charter extension

In August 2026, the charterer of the M/V Dukeship agreed to an extension of the time charter agreement, providing for a new redelivery window from January 2028 to March 2028. The daily hire is based on the 5 T/C routes of the BCI, and all other main terms of the time charter remain materially unchanged.

M/V Squireship – Time charter extension

In September 2026, the charterer of the M/V Squireship agreed to extend the time charter agreement in direct continuation from the previous agreement. The extension period will commence in January 2027, for a minimum of January 2028 and a maximum of March 2028. The daily hire is based on the 5 T/C routes of the BCI, and all other main terms of the time charter remain materially unchanged.

M/Vs Dukeship and Squireship – Hire Conversions  

In September 2026, the Company converted the M/V Dukeship’s charter hire to a fixed daily gross rate exceeding $35,000 for 2027.

In November 2026, the Company converted the M/V Squireship’s charter hire to a fixed daily gross rate exceeding $29,100 for 2027.

Financing Updates

M/V Dukeship – Financing

In November 2026, the Company agreed main terms with a Japanese counterparty for a sale and leaseback agreement to fully finance the purchase obligation under the current bareboat charter of the M/V Dukeship, well in advance of its due date in the third quarter of 2027. The transaction remains subject to credit committee approval and definite documentation.

_______________
⁴ This guidance is based on certain assumptions, and the Company cannot provide assurance that these TCE rate estimates or projected utilization rates will be realized. TCE estimates include certain floating (index) to fixed rate conversions concluded in previous periods. For vessels on index-linked T/Cs, the TCE rate realized will vary with the underlying index, and for the purposes of this guidance, the BPI-82 rate assumed for the remaining operating days of the quarter for an index-linked T/C is equal to an average of $19,029 per day (based on the FFA curve as of November 5, 2026). Spot estimates are provided using the load-to-discharge method of accounting. The rates quoted are for days currently contracted. Increased ballast days at the end of the quarter will reduce the additional revenues that can be booked based on the accounting cut-offs and therefore the resulting TCE rate will be reduced accordingly.

United Maritime Corporation Unaudited Condensed Consolidated Balance Sheets (In thousands of U.S. Dollars)
		September 30, 2026			December 31, 2025*
ASSETS
Cash and cash equivalents and restricted cash		24,410			14,564
Vessels, net, Right-of-use assets and Vessel held for sale		126,206			99,885
Other assets		6,531			24,232
TOTAL ASSETS		157,147			138,681
LIABILITIES AND STOCKHOLDERS’ EQUITY
Long-term debt, finance lease liability and other financial liabilities, net of deferred finance costs		83,736			64,839
Other liabilities		17,287			17,376
Stockholders’ equity		56,124			56,466
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		157,147			138,681

* Derived from the audited consolidated financial statements as of the period as of that date

United Maritime Corporation Unaudited Condensed Consolidated Statements of Operations (In thousands of U.S. Dollars, except for share and per share data)
		Three months ended September 30,				Nine months ended September 30,
		2026		2025		2026			2025
Vessel revenue, net		11,970		10,966		29,907			31,193
Expenses:
Voyage expenses		(710	)	(2,242	)	(1,445	)		(4,818	)
Vessel operating expenses		(3,783	)	(3,673	)	(10,373	)		(12,709	)
Management fees		(456	)	(477	)	(1,311	)		(1,652	)
General and administration expenses		(1,111	)	(1,196	)	(3,740	)		(2,628	)
Depreciation and amortization		(2,703	)	(2,377	)	(6,986	)		(8,817	)
Loss on forward freight agreements		(6	)	–		(6	)		–
Gain on disposal of equity method investment		–		–		523			–
Gain on sale of vessels		1,811		1,928		1,967			1,773
Operating income		5,012		2,929		8,536			2,342
Other income / (expenses):
Interest and finance costs		(1,159	)	(1,494	)	(3,401	)		(5,186	)
Interest and finance costs – related party		(182	)	–		(464	)		(48	)
Interest income		36		65		135			105
Loss on extinguishment of debt		(495	)	(407	)	(608	)		(640	)
Gain on consolidation		–		–		–			1,268
Loss on liquidation of subsidiary		(58	)	–		(58	)		–
Loss on equity method investment		–		(6	)	(7	)		(50	)
Other income		15		–		63			–
Other, net		50		(21	)	44			(232	)
Total other expenses, net:		(1,793	)	(1,863	)	(4,296	)		(4,783	)
Net income / (loss)		3,219		1,066		4,240			(2,441	)
Net income / (loss) attributable to common shareholders, basic		3,180		1,066		4,169			(2,412	)
Net income / (loss) attributable to common shareholders, diluted		3,180		1,066		4,259			(2,412	)
Earnings / (loss) per common share, basic		0.34		0.12		0.46			(0.27	)
Earnings / (loss) per common shares, diluted		0.31		0.12		0.43			(0.27	)
Weighted average number of common shares outstanding, basic		9,241,792		8,917,144		9,121,465			8,841,632
Weighted average number of common shares outstanding, diluted		10,406,256		8,917,144		9,834,583			8,841,632

United Maritime Corporation Unaudited Condensed Consolidated Cash Flow Data (In thousands of U.S. Dollars)
		Nine months ended September 30,
		2026		2025
Net cash provided by / (used in) operating activities		9,959		(44	)
Net cash provided by investing activities		31,101		45,737
Net cash used in financing activities		(31,130	)	(32,333	)

About United Maritime Corporation

United Maritime Corporation is an international shipping company specializing in worldwide seaborne transportation services. The Company operates a fleet of five dry bulk vessels, comprising two Capesize, one Kamsarmax and two Panamax vessels, with an aggregate cargo carrying capacity of 589,899 dwt. Upon completion of the aforementioned acquisition of the M/V Friendship, the Company’s operating fleet will consist of six vessels (three Capesize, one Kamsarmax and two Panamax vessels), with an aggregate cargo carrying capacity of 766,851 dwt.

The Company is incorporated under the laws of the Republic of the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “USEA”.

Please visit the Company’s website at: www.unitedmaritime.gr.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, including with respect to declaration of dividends, market trends and cash distributions. Words such as “may”, “should”, “expects”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s operating or financial results; the Company’s liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, impacts of litigation, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations outside the United States; risks arising from trade disputes between the U.S. and China, including the re-imposition of reciprocal port fees; broader market impacts arising from trade disputes or war (or threatened war) or international hostilities, such as between the U.S. and Israel and Iran, the U.S. and Venezuela, China and Taiwan, and Russia and Ukraine; risks associated with the length and severity of pandemics; and other factors listed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its most recent annual report on Form 20-F. The Company’s filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information please contact:

United Investor Relations
Tel: +30 213 0181 522
E-mail: ir@usea.gr

Capital Link, Inc.
Paul Lampoutis
230 Park Avenue Suite 1540
New York, NY 10169
Tel: +1 212 661 7566
E-mail: usea@capitallink.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a4bd94b7-a49d-4554-83dc-59ec22ba3cb6

Quarterly Net Income Triples to $3.2 Million as Capital Reallocation Lifts Fleet TCE 37%

Further Expands Capesize Fleet; Fixes M/V Dukeship and M/V Squireship for 2027 at Attractive Charter Rates

Highlights (in million USD, except EPS, LPS and TCE)	Q3 2026		Q3 2025		9M 2026		9M 2025			9M 2026 vs 9M 2025
Net Revenues	$	12.0	$	11.0	$	29.9	$	31.2
Net Income / (Loss)	$	3.2	$	1.1	$	4.2	$	(2.4	)
Adjusted Net Income / (Loss)1	$	4.0	$	1.6	$	5.7	$	(2.6	)
EBITDA1	$	7.2	$	4.9	$	15.0	$	11.5		+30	%
Adjusted EBITDA1	$	8.0	$	5.4	$	16.4	$	11.4		+45	%
TCE2	$	20,737	$	15,093	$	18,446	$	13,436		+37	%
Earnings / (Loss) per share Basic	$	0.34	$	0.12	$	0.46	$	(0.27	)
Earnings / (Loss) per share Diluted	$	0.31	$	0.12	$	0.43	$	(0.27	)
Adjusted Earnings / (Loss) per share Basic1	$	0.43	$	0.18	$	0.62	$	(0.29	)
Adjusted Earnings / (Loss) per share Diluted1	$	0.38	$	0.18	$	0.58	$	(0.29	)

Other Highlights and Developments:

• Strong Third Quarter Financial Performance Reflecting Benefits of Strategic Fleet Repositioning
  • Quarterly Net Income of $3.2 million and Adjusted EBITDA of $8.0 million, with fleet TCE increasing 37% year-over-year to $20,737 per day.
  • Nine-month Adjusted EBITDA increased 45% to $16.4 million, with fleet TCE up 37% to $18,446 per day.
• Cash Dividend for the Third Quarter Doubled to $0.20 Per Share
  • 16^th consecutive quarterly dividend, bringing cumulative cash distributions since November 2022 to $2.24 per share, or approximately $18.7 million.³
• Continued Capital Reallocation Through Further Capesize Expansion
  • Agreed to acquire the 2009-built Capesize vessel M/V Friendship, with delivery expected in early Q1 2027.
  • Completed the sale of the 2011-built Panamax M/V Exelixsea, generating $8.7 million of net cash proceeds and a gain of $1.8 million.

_______________
¹ Adjusted Earnings / (Loss) per share, Adjusted Net Income / (Loss), EBITDA and Adjusted EBITDA are non-GAAP measures. Please see the reconciliation below of Adjusted Earnings / (Loss) per share, Adjusted Net Income / (loss), EBITDA and Adjusted EBITDA to Net Income / (Loss), the most directly comparable U.S. GAAP measure.
² Time Charter Equivalent (“TCE”) rate is a non-GAAP measure. Please see the reconciliation below of TCE rate to Net Revenues from vessels, the most directly comparable U.S. GAAP measure.

GLYFADA, Greece, Nov. 12, 2026 (GLOBE NEWSWIRE) — United Maritime Corporation (“United” or the “Company”) (NASDAQ: USEA) announced today its financial results for the third quarter and nine months ended September 30, 2026. The Company also declared a quarterly dividend of $0.20 per common share for the third quarter of 2026.

For the quarter ended September 30, 2026, the Company generated Net Revenues of $12.0 million, compared to $11.0 million in the prior-year period, despite fewer ownership days resulting from its ongoing fleet repositioning strategy. Net Income and Adjusted Net Income for the quarter were $3.2 million and $4.0 million, respectively, compared to $1.1 million and $1.6 million, respectively, in the third quarter of 2025. Adjusted EBITDA for the quarter was $8.0 million, compared to $5.4 million for the same period of 2025. Fleet TCE increased 37% year-over-year to $20,737 per day, driven by stronger dry bulk market conditions and the increased earnings contribution of the Company’s Capesize vessels.

For the first nine months of 2026, the Company generated Net Revenues of $29.9 million and Adjusted EBITDA of $16.4 million, compared to $31.2 million and $11.4 million, respectively, in the same period of 2025. Net Income and Adjusted Net Income for the period were $4.2 million and $5.7 million, respectively, compared to Net Loss of $2.4 million and Adjusted Net Loss of $2.6 million in the respective period of 2025. Fleet TCE increased 37% to $18,446 per day year-over-year. The average daily OPEX was $6,607 compared to $6,323 for the same period of 2025, reflecting the higher share of Capesize vessels in the fleet.

As of September 30, 2026, United held $24.4 million in cash, cash equivalents and restricted cash, with shareholders’ equity standing at $56.1 million, while bank debt, finance lease liabilities and other financial liabilities, net of deferred finance costs stood at $83.7 million. Total debt declined by $10.5 million during the quarter, primarily due to the repayment of the debt associated with the M/V Exelixsea. The book value of the Company’s fleet as of September 30, 2026, stood at $126.2 million, reflecting the Company’s strategic expansion into the Capesize segment.

Stamatis Tsantanis, the Company’s Chairman & Chief Executive Officer, stated:

“Our capital reallocation is beginning to generate meaningful returns: third-quarter Net Income tripled to $3.2 million and Adjusted EBITDA rose 48% to $8.0 million. Our fleet earned $20,737 per day – up 37% year-over-year, 11% above the second quarter and ahead of our guidance. We are now beginning to see the operating leverage benefits of our Capesize-weighted fleet.

Our board has declared a quarterly dividend of $0.20 per share – double the dividend declared for the second quarter. This represents the Company’s 16th consecutive quarterly cash distribution. With our two operating Capesizes fixed for 2027, contracted cash flows support this dividend.

Our third Capesize, the 2009-built M/V Friendship, is expected to be delivered in early Q1 2027, funded with debt and the proceeds of our recent asset sales. Capesizes will then represent approximately 69% of our fleet’s carrying capacity. Our strategy remains unchanged: divest lower-performing assets and redeploy capital into higher-earning assets that generate stronger results for our shareholders.

Four of our five vessels are fixed for the fourth quarter, and we expect a Q4 TCE of approximately $22,689 per day, representing a further 10% increase. More importantly, our two operating Capesizes are now fixed for the whole of 2027 – the M/V Dukeship at over $35,000 per day and the M/V Squireship at over $29,100 per day. Together, these charters represent approximately $23.1 million of contracted gross hire from two vessels, while the remainder of our fleet retains exposure to potential upside in the market.

The dry bulk sector performed very strongly in the third quarter, driven mainly by record bauxite volumes and continued ton-mile growth in iron ore, while grain and coal volumes have also remained supportive throughout the year. On the supply side, vessel routing inefficiencies, including those associated with the Panama Canal, and ongoing geopolitical disruptions have kept effective fleet growth limited. Looking ahead, market fundamentals remain constructive, with a relatively modest orderbook set against a rapidly aging fleet, which we believe should continue to support freight rates.

Our priorities are clear: build on the earnings gains achieved to date, continue reallocating capital into higher-earning assets, and convert stronger performance into sustainable cash distributions. United is well positioned to deliver on all three.”

_______________
³ The amounts include the 16th consecutive quarterly cash dividend declared but not yet paid.

Company Fleet:

Vessel Name	Sector	Capacity (DWT)	Year Built	Yard	Employment Type	Minimum T/C expiration	Maximum T/C expiration(1)
Dukeship(2)	Capesize	181,453	2010	Sasebo	T/C Index Linked(3)	Jan-28	Mar-28
Squireship	Capesize	170,018	2010	Sungdong	T/C Index Linked(3)	Jan-28	Mar-28
Nisea	Kamsarmax	82,235	2016	Oshima	T/C Index Linked(3)	Jul-27	Sep-27
Chrisea	Panamax	78,173	2013	Shin Kurushima	T/C Index Linked(3)	Mar-27	Jul-27
Synthesea	Panamax	78,020	2015	Sasebo	T/C Index Linked(3)	Jan-28	Apr-28
Total/Average age		589,899	13.8 years
Vessel to be delivered
Friendship(4)	Capesize	176,952	2009	Namura	T/C Index Linked(3)	Apr-27	Sep-27

(1) The latest redelivery dates do not include any additional optional periods.

(2) The vessel is technically and commercially operated by the Company on the basis of an 18-month bareboat charter-in contract with the owners of the vessel, including a purchase obligation at the end of the bareboat charter.

(3) “T/C” refers to a time charter agreement. Under these index-linked T/Cs, the Company has the option to convert the index-linked rate to fixed for a minimum period of two months, based on the prevailing FFA Rates for the selected period, and has done so for certain vessels as part of its freight hedging strategy, as described below under “Fourth Quarter 2026 TCE Rate Guidance”.

(4) The vessel is expected to be delivered in early Q1 2027.

Fleet Data:

	Q3 2026			Q3 2025			9M 2026			9M 2025
Ownership days (1)		547			583			1,570			2,010
Operating days (2)		543			578			1,543			1,963
Fleet utilization (3)		99.3	%		99.1	%		98.3	%		97.7	%
TCE rate (4)	$	20,737		$	15,093		$	18,446		$	13,436
Daily Vessel Operating Expenses (5)	$	6,916		$	6,300		$	6,607		$	6,323

(1) Ownership days are the total number of calendar days in a period during which the vessels in a fleet have been owned or chartered. Ownership days are an indicator of the size of the Company’s fleet over a period and affect both the amount of revenues and the amount of expenses that the Company recorded during a period.

(2) Operating days are the number of available days in a period less the aggregate number of days that the vessels are off-hire due to unforeseen circumstances. Available days are the number of ownership days less the aggregate number of days that our vessels are off-hire due to major repairs, dry-dockings, lay-up or special or intermediate surveys. Operating days include the days that our vessels are on ballast voyages without having finalized agreements for their next employment. The Company’s calculation of operating days may not be comparable to that reported by other companies.

(3) Fleet utilization is the percentage of time that the vessels are generating revenue and is determined by dividing operating days by ownership days for the relevant period.

(4) TCE rate is defined as the Company’s net revenue less voyage expenses during a period divided by the number of the Company’s operating days during the period. Voyage expenses include port charges, bunker (fuel oil and diesel oil) expenses, canal charges and other commissions. The Company includes the TCE rate, a non-GAAP measure, as it believes it provides additional meaningful information in conjunction with net revenues from vessels, the most directly comparable U.S. GAAP measure, and because it assists the Company’s management in making decisions regarding the deployment and use of our vessels and because the Company believes that it provides useful information to investors regarding our financial performance. The Company’s calculation of TCE rate may not be comparable to that reported by other companies. The following table reconciles the Company’s net revenues from vessels to the TCE rate.

(In thousands of U.S. Dollars, except operating days and TCE rate)

	Q3 2026		Q3 2025		9M 2026		9M 2025
Vessel revenue, net		11,970		10,966		29,907		31,193
Less: Voyage expenses		710		2,242		1,445		4,818
Time charter equivalent revenues		11,260		8,724		28,462		26,375
Operating days		543		578		1,543		1,963
TCE rate	$	20,737	$	15,093	$	18,446	$	13,436

(5) Vessel operating expenses include crew costs, provisions, deck and engine stores, lubricants, insurance, maintenance and repairs. Daily Vessel Operating Expenses are calculated by dividing vessel operating expenses, excluding pre-delivery costs of acquired vessels, if applicable, by ownership days for the relevant time periods. The Company’s calculation of daily vessel operating expenses may not be comparable to that reported by other companies. The following table reconciles the Company’s vessel operating expenses to daily vessel operating expenses.

(In thousands of U.S. Dollars, except ownership days and Daily Vessel Operating Expenses) 

	Q3 2026		Q3 2025		9M 2026		9M 2025
Vessel operating expenses		3,783		3,673		10,373		12,709
Ownership days		547		583		1,570		2,010
Daily Vessel Operating Expenses	$	6,916	$	6,300	$	6,607	$	6,323

Net Income / (Loss) to EBITDA and Adjusted EBITDA Reconciliation:

(In thousands of U.S. Dollars)

	Q3 2026	Q3 2025	9M 2026	9M 2025
Net income / (loss)	3,219	1,066	4,240	(2,441	)
Interest and finance costs, net	1,304	1,429	3,730	5,129
Depreciation and amortization	2,703	2,377	6,986	8,817
EBITDA	7,226	4,872	14,956	11,505
Stock based compensation	205	118	796	427
Loss on extinguishment of debt	495	407	608	640
Loss on liquidation of subsidiary	58	–	58	–
Loss on forward freight agreements	6	–	6	–
Gain on consolidation	–	–	–	(1,268	)
Loss on equity method investment	–	6	7	50
Adjusted EBITDA	7,990	5,403	16,431	11,354

Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) represents the sum of net income, net interest and finance costs, depreciation and amortization and, if any, income taxes during a period. EBITDA and Adjusted EBITDA are not recognized measurements under U.S. GAAP. Adjusted EBITDA represents EBITDA adjusted to exclude stock-based compensation, loss on extinguishment of debt, loss on liquidation of subsidiary, loss on forward freight agreements, gain on consolidation and loss on equity method investment, which the Company believes are not indicative of the ongoing performance of its core operations.

EBITDA and Adjusted EBITDA are presented as we believe that these measures are useful to investors as a widely used means of evaluating operating profitability. EBITDA and Adjusted EBITDA as presented here may not be comparable to similarly titled measures presented by other companies. These non-GAAP measures should not be considered in isolation from, as a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP.

Net Income / (Loss) and Adjusted Net Income / (Loss) Reconciliation and calculation of Adjusted Earnings / (Loss) Per Share

(In thousands of U.S. Dollars)

	Q3 2026	Q3 2025	9M 2026	9M 2025
Net income / (loss)	3,219	1,066	4,240	(2,441	)
Stock based compensation	205	118	796	427
Loss on extinguishment of debt	495	407	608	640
Gain on consolidation	–	–	–	(1,268	)
Loss on equity method investment	–	6	7	50
Loss on forward freight agreements	6	–	6	–
Loss on liquidation of subsidiary	58	–	58	–
Adjusted net income / (loss)	3,983	1,597	5,715	(2,592	)
Adjusted net income / (loss) – common stockholders, basic	3,944	1,597	5,644	(2,563	)
Adjusted net income / (loss) – common stockholders, diluted	3,944	1,597	5,734	(2,563	)
Adjusted earnings / (loss) per common share, basic	0.43	0.18	0.62	(0.29	)
Adjusted earnings / (loss) per common share, diluted	0.38	0.18	0.58	(0.29	)
Weighted average number of common shares outstanding, basic	9,241,792	8,917,144	9,121,465	8,841,632
Weighted average number of common shares outstanding, diluted	10,406,256	8,917,144	9,834,583	8,841,632

To derive Adjusted Net Income / (Loss) and Adjusted Earnings / (Loss) Per Share, both non-GAAP measures, from Net income / (Loss), we exclude certain non-cash items, as provided in the table above. We believe that Adjusted Net Income / (Loss) and Earnings / (Loss) Per Share assist our management and investors by increasing the comparability of our performance from period to period since each such measure eliminates the effects of such non-cash items as stock-based compensation, loss on extinguishment of debt, gain on consolidation, loss on equity method investment, loss on forward freight agreements, loss on liquidation of subsidiary and other items which may vary from year to year, for reasons unrelated to overall operating performance. In addition, we believe that the presentation of the respective measures provides investors with supplemental data relating to our results of operations, and therefore, with a more complete understanding of factors affecting our business than with GAAP measures alone. Our method of computing Adjusted Net Income / (Loss) and Adjusted Earnings / (Loss) Per Share may not necessarily be comparable to other similarly titled captions of other companies due to differences in methods of calculation.

Fourth Quarter 2026 TCE Rate Guidance:

As of the date hereof, approximately 88% of the Company fleet’s expected operating days in the fourth quarter of 2026 have been fixed at an estimated TCE rate of approximately $23,339 per day. Assuming that for the remaining operating days of our index-linked T/Cs, the BPI-82 rate will be equal to an average of $19,029 per day (based on the FFA curve of November 5, 2026), our estimated TCE for the fourth quarter of 2026 is approximately $22,689⁴ per day. Our TCE rate guidance for the fourth quarter of 2026 includes the already performed conversions of index-linked charters to fixed for the period.

The following table provides the breakdown of index-linked charters and fixed-rate charters in the fourth quarter of 2026:

	Operating Days	TCE Rate
TCE – fixed rate (including index-linked conversions)	365	$	23,715
TCE – index-linked	92	$	18,624
Total / Average	457	$	22,689

Third Quarter and Recent Developments:

Dividend Distribution for Q2 2026 and Declaration of Q3 2026 Dividend

On October 9, 2026, the Company paid a quarterly dividend of $0.10 per common share, for the second quarter of 2026, to all shareholders of record as of September 25, 2026.

The Company has declared a quarterly cash dividend of $0.20 per common share for the third quarter of 2026 payable on or about January 8, 2027, to all shareholders of record as of December 24, 2026.

Vessel transactions and commercial updates

Sale of M/V Exelixsea

In September 2026, the Company delivered the 76,361 dwt M/V Exelixsea, built in 2011, to her new owners. The vessel was sold for a gross consideration of approximately $17.5 million, generating net cash proceeds of approximately $8.7 million following repayment of the associated debt. In addition, the transaction resulted in a gain on sale of approximately $1.8 million, which was recognized in the third quarter of 2026.

Acquisition of M/V Friendship

In November 2026, the Company agreed main terms with Seanergy Maritime Holdings Corp. (“Seanergy”), for the acquisition of the 2009-built Capesize bulk carrier M/V Friendship, constructed in Japan, for an aggregate purchase price of $33.0 million. A special independent and disinterested committee of the Company’s board of directors negotiated and approved the terms. The acquisition remains subject to the existing financier’s approval and parties entering into final documentation. The vessel is expected to be delivered to the Company in early Q1 2027. The acquisition is expected to be financed through a combination of debt financing and proceeds generated from recent asset monetization initiatives.

M/V Dukeship – Time charter extension

In August 2026, the charterer of the M/V Dukeship agreed to an extension of the time charter agreement, providing for a new redelivery window from January 2028 to March 2028. The daily hire is based on the 5 T/C routes of the BCI, and all other main terms of the time charter remain materially unchanged.

M/V Squireship – Time charter extension

In September 2026, the charterer of the M/V Squireship agreed to extend the time charter agreement in direct continuation from the previous agreement. The extension period will commence in January 2027, for a minimum of January 2028 and a maximum of March 2028. The daily hire is based on the 5 T/C routes of the BCI, and all other main terms of the time charter remain materially unchanged.

M/Vs Dukeship and Squireship – Hire Conversions  

In September 2026, the Company converted the M/V Dukeship’s charter hire to a fixed daily gross rate exceeding $35,000 for 2027.

In November 2026, the Company converted the M/V Squireship’s charter hire to a fixed daily gross rate exceeding $29,100 for 2027.

Financing Updates

M/V Dukeship – Financing

In November 2026, the Company agreed main terms with a Japanese counterparty for a sale and leaseback agreement to fully finance the purchase obligation under the current bareboat charter of the M/V Dukeship, well in advance of its due date in the third quarter of 2027. The transaction remains subject to credit committee approval and definite documentation.

_______________
⁴ This guidance is based on certain assumptions, and the Company cannot provide assurance that these TCE rate estimates or projected utilization rates will be realized. TCE estimates include certain floating (index) to fixed rate conversions concluded in previous periods. For vessels on index-linked T/Cs, the TCE rate realized will vary with the underlying index, and for the purposes of this guidance, the BPI-82 rate assumed for the remaining operating days of the quarter for an index-linked T/C is equal to an average of $19,029 per day (based on the FFA curve as of November 5, 2026). Spot estimates are provided using the load-to-discharge method of accounting. The rates quoted are for days currently contracted. Increased ballast days at the end of the quarter will reduce the additional revenues that can be booked based on the accounting cut-offs and therefore the resulting TCE rate will be reduced accordingly.

United Maritime Corporation Unaudited Condensed Consolidated Balance Sheets (In thousands of U.S. Dollars)
		September 30, 2026			December 31, 2025*
ASSETS
Cash and cash equivalents and restricted cash		24,410			14,564
Vessels, net, Right-of-use assets and Vessel held for sale		126,206			99,885
Other assets		6,531			24,232
TOTAL ASSETS		157,147			138,681
LIABILITIES AND STOCKHOLDERS’ EQUITY
Long-term debt, finance lease liability and other financial liabilities, net of deferred finance costs		83,736			64,839
Other liabilities		17,287			17,376
Stockholders’ equity		56,124			56,466
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		157,147			138,681

* Derived from the audited consolidated financial statements as of the period as of that date

United Maritime Corporation Unaudited Condensed Consolidated Statements of Operations (In thousands of U.S. Dollars, except for share and per share data)
		Three months ended September 30,				Nine months ended September 30,
		2026		2025		2026			2025
Vessel revenue, net		11,970		10,966		29,907			31,193
Expenses:
Voyage expenses		(710	)	(2,242	)	(1,445	)		(4,818	)
Vessel operating expenses		(3,783	)	(3,673	)	(10,373	)		(12,709	)
Management fees		(456	)	(477	)	(1,311	)		(1,652	)
General and administration expenses		(1,111	)	(1,196	)	(3,740	)		(2,628	)
Depreciation and amortization		(2,703	)	(2,377	)	(6,986	)		(8,817	)
Loss on forward freight agreements		(6	)	–		(6	)		–
Gain on disposal of equity method investment		–		–		523			–
Gain on sale of vessels		1,811		1,928		1,967			1,773
Operating income		5,012		2,929		8,536			2,342
Other income / (expenses):
Interest and finance costs		(1,159	)	(1,494	)	(3,401	)		(5,186	)
Interest and finance costs – related party		(182	)	–		(464	)		(48	)
Interest income		36		65		135			105
Loss on extinguishment of debt		(495	)	(407	)	(608	)		(640	)
Gain on consolidation		–		–		–			1,268
Loss on liquidation of subsidiary		(58	)	–		(58	)		–
Loss on equity method investment		–		(6	)	(7	)		(50	)
Other income		15		–		63			–
Other, net		50		(21	)	44			(232	)
Total other expenses, net:		(1,793	)	(1,863	)	(4,296	)		(4,783	)
Net income / (loss)		3,219		1,066		4,240			(2,441	)
Net income / (loss) attributable to common shareholders, basic		3,180		1,066		4,169			(2,412	)
Net income / (loss) attributable to common shareholders, diluted		3,180		1,066		4,259			(2,412	)
Earnings / (loss) per common share, basic		0.34		0.12		0.46			(0.27	)
Earnings / (loss) per common shares, diluted		0.31		0.12		0.43			(0.27	)
Weighted average number of common shares outstanding, basic		9,241,792		8,917,144		9,121,465			8,841,632
Weighted average number of common shares outstanding, diluted		10,406,256		8,917,144		9,834,583			8,841,632

United Maritime Corporation Unaudited Condensed Consolidated Cash Flow Data (In thousands of U.S. Dollars)
		Nine months ended September 30,
		2026		2025
Net cash provided by / (used in) operating activities		9,959		(44	)
Net cash provided by investing activities		31,101		45,737
Net cash used in financing activities		(31,130	)	(32,333	)

About United Maritime Corporation

United Maritime Corporation is an international shipping company specializing in worldwide seaborne transportation services. The Company operates a fleet of five dry bulk vessels, comprising two Capesize, one Kamsarmax and two Panamax vessels, with an aggregate cargo carrying capacity of 589,899 dwt. Upon completion of the aforementioned acquisition of the M/V Friendship, the Company’s operating fleet will consist of six vessels (three Capesize, one Kamsarmax and two Panamax vessels), with an aggregate cargo carrying capacity of 766,851 dwt.

The Company is incorporated under the laws of the Republic of the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “USEA”.

Please visit the Company’s website at: www.unitedmaritime.gr.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, including with respect to declaration of dividends, market trends and cash distributions. Words such as “may”, “should”, “expects”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s operating or financial results; the Company’s liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, impacts of litigation, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations outside the United States; risks arising from trade disputes between the U.S. and China, including the re-imposition of reciprocal port fees; broader market impacts arising from trade disputes or war (or threatened war) or international hostilities, such as between the U.S. and Israel and Iran, the U.S. and Venezuela, China and Taiwan, and Russia and Ukraine; risks associated with the length and severity of pandemics; and other factors listed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its most recent annual report on Form 20-F. The Company’s filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information please contact:

United Investor Relations
Tel: +30 213 0181 522
E-mail: ir@usea.gr

Capital Link, Inc.
Paul Lampoutis
230 Park Avenue Suite 1540
New York, NY 10169
Tel: +1 212 661 7566
E-mail: usea@capitallink.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a4bd94b7-a49d-4554-83dc-59ec22ba3cb6

Dermatest®-rated skin compatibility “Excellent” and clinical studies by CE.way Regulatory Consultants found significant improvements in skin hydration and elasticity with visible reductions in the appearance of wrinkles in participants

SANTA MONICA, CA, Nov. 12, 2026 (GLOBE NEWSWIRE) — Oliveda International, Inc. (OTCID: OLVI) today announced that the waterless skincare brand, Oliveda, has been awarded “Excellent” ratings from Dermatest® and CE.way Regulatory Consultants alongside four-week clinical results for skin hydration, elasticity and the appearance of wrinkles.

What happens when you build skincare around the olive leaf instead of added water? Oliveda, the waterless skincare brand from Olive Tree People Inc., has been awarded Dermatest’s “Excellent” rating for skin compatibility.

In separate four-week clinical studies, CE.way Regulatory Consultants also rated the tested formulations “Excellent.” The studies found statistically significant improvements in skin hydration and, in formulations evaluated for elasticity, statistically significant improvements in that measure as well (p < 0.05). Facial imaging showed visible reductions in the appearance of wrinkles in some participants.

“We started with a question the beauty industry rarely asks: ‘What could skincare become if we changed the very first ingredient?’” said Thomas Lommel, founder of Olive Tree People. “We built our formulas around the olive leaf. These results show what that decision can mean for skin in just four weeks.”

Oliveda’s approach begins in its own biodynamic olive groves. The brand uses an olive leaf cell elixir containing hydroxytyrosol as the foundation of its waterless skincare. It’s an ingredient Oliveda has worked with for years, and a formulation choice now backed by measured improvements in hydration and elasticity.

About Oliveda
Oliveda is a waterless skincare brand from Olive Tree People, founded by Thomas Lommel. Its formulations draw on ingredients from the company’s own biodynamic olive groves, including olive leaf cell elixir and cold-pressed Arbequina olive oil.

About Olive Tree People
Olive Tree People is a pioneer and leading force in waterless beauty. Instead of using the conventional water phase found in most skincare products, the company replaces water with its proprietary olive leaf cell elixir and combines it with powerful olive-tree ingredients, including Hydroxytyrosol.

Founded by olive tree farmer Thomas Lommel, Olive Tree People develops skincare, beauty and holistic experiences based on more than 20 years of work with mountain olive trees and the principles of Olive Tree Therapy.

About Oliveda International, Inc. 
Oliveda International, Inc. and its subsidiary, Olive Tree People Inc., as well as the European companies, Olive Tree People Europe AG, Oliveda Deutschland GmbH, and Olive Tree Farmers SL, were founded by the German real estate investor Thomas Lommel. The companies possess over 20 years of experience in management and organic certification growing mountain olive trees; in the extraction of first-class, internationally award-winning extra virgin olive oils; the extraction of hydroxytyrosol; and the production and distribution of cosmetic and holistic waterless products related to the olive tree.  Lommel is the inventor of the “Olive Tree Therapy 10 Years in 14 Days” as well as the inventor of olive matcha, which is based on the ground olive leaf. Also unique is the coffee replacement developed by Lommel, which is based on the olive leaf and hydroxytyrosol.  In addition, Lommel is successfully active in the rapidly growing mindfulness industry with the olive tree sound bath meditation he developed and the frequencies of his olive trees, which he makes available worldwide.

In addition to the registered beauty brands, Oliveda and LA Dope, as well as the brands Olive Rose, OLIVE re:connected to Nature, The Intuition of Nature, Olive Mush, Is That Matty?, and Baby & Mom. Lommel is the region’s largest conservationist and protector of over 30,000 one-hundred-year-old mountain olive trees. With his Thomas Lommel Foundation, he brings the water that he does not use into his waterless beauty products to the people of Africa by building water wells on site.

The company’s direct-to-consumer network includes tens of thousands of Waterless Beauty Consultants in North America and Europe. In addition to online sales and a Europe-wide branch network of thousands of retail stores, Oliveda Deutschland GmbH operates its own flagship stores in Berlin and Düsseldorf.

The brand’s treatment concepts are unique worldwide, and their effectiveness has been confirmed by conventional medicine.  Read our book The Olive Tree Therapy 10 Years in 14 Days. Waterless beauty has been called “The Next Big Thing” in articles in U.S. Vogue, Harper’s Bazaar, InStyle, Elle, Madame, Forbes, and many other industry publications, as well as by Mintel, a world-leading futurology institute.  Gigi Hadid and many other celebrities are already Oliveda fans and support its success.  Further information on Oliveda International, Inc. and its subsidiaries and associate companies and brands can be found at www.olivetreepeople.com

Forward-Looking Statements
This press release may contain statements, estimates or projections that constitute “forward-looking statements” pursuant to the safe harbor provisions of the U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties, which may be found in the Company’s filings with OTC Markets Group Inc., that could cause actual results to differ materially from the Company’s historical experience and present expectations or projections. Investors should not place undue reliance on forward-looking statements, which speak only as of the date they are made.  The Company expressly disclaims any obligation or intention to publicly update or revise any forward-looking statements unless otherwise required by law.

CONTACT: OLVI Investor Relations
619-202-7456
olvi@advanceprgroup.com

Dermatest®-rated skin compatibility “Excellent” and clinical studies by CE.way Regulatory Consultants found significant improvements in skin hydration and elasticity with visible reductions in the appearance of wrinkles in participants

SANTA MONICA, CA, Nov. 12, 2026 (GLOBE NEWSWIRE) — Oliveda International, Inc. (OTCID: OLVI) today announced that the waterless skincare brand, Oliveda, has been awarded “Excellent” ratings from Dermatest® and CE.way Regulatory Consultants alongside four-week clinical results for skin hydration, elasticity and the appearance of wrinkles.

What happens when you build skincare around the olive leaf instead of added water? Oliveda, the waterless skincare brand from Olive Tree People Inc., has been awarded Dermatest’s “Excellent” rating for skin compatibility.

In separate four-week clinical studies, CE.way Regulatory Consultants also rated the tested formulations “Excellent.” The studies found statistically significant improvements in skin hydration and, in formulations evaluated for elasticity, statistically significant improvements in that measure as well (p < 0.05). Facial imaging showed visible reductions in the appearance of wrinkles in some participants.

“We started with a question the beauty industry rarely asks: ‘What could skincare become if we changed the very first ingredient?’” said Thomas Lommel, founder of Olive Tree People. “We built our formulas around the olive leaf. These results show what that decision can mean for skin in just four weeks.”

Oliveda’s approach begins in its own biodynamic olive groves. The brand uses an olive leaf cell elixir containing hydroxytyrosol as the foundation of its waterless skincare. It’s an ingredient Oliveda has worked with for years, and a formulation choice now backed by measured improvements in hydration and elasticity.

About Oliveda
Oliveda is a waterless skincare brand from Olive Tree People, founded by Thomas Lommel. Its formulations draw on ingredients from the company’s own biodynamic olive groves, including olive leaf cell elixir and cold-pressed Arbequina olive oil.

About Olive Tree People
Olive Tree People is a pioneer and leading force in waterless beauty. Instead of using the conventional water phase found in most skincare products, the company replaces water with its proprietary olive leaf cell elixir and combines it with powerful olive-tree ingredients, including Hydroxytyrosol.

Founded by olive tree farmer Thomas Lommel, Olive Tree People develops skincare, beauty and holistic experiences based on more than 20 years of work with mountain olive trees and the principles of Olive Tree Therapy.

About Oliveda International, Inc. 
Oliveda International, Inc. and its subsidiary, Olive Tree People Inc., as well as the European companies, Olive Tree People Europe AG, Oliveda Deutschland GmbH, and Olive Tree Farmers SL, were founded by the German real estate investor Thomas Lommel. The companies possess over 20 years of experience in management and organic certification growing mountain olive trees; in the extraction of first-class, internationally award-winning extra virgin olive oils; the extraction of hydroxytyrosol; and the production and distribution of cosmetic and holistic waterless products related to the olive tree.  Lommel is the inventor of the “Olive Tree Therapy 10 Years in 14 Days” as well as the inventor of olive matcha, which is based on the ground olive leaf. Also unique is the coffee replacement developed by Lommel, which is based on the olive leaf and hydroxytyrosol.  In addition, Lommel is successfully active in the rapidly growing mindfulness industry with the olive tree sound bath meditation he developed and the frequencies of his olive trees, which he makes available worldwide.

In addition to the registered beauty brands, Oliveda and LA Dope, as well as the brands Olive Rose, OLIVE re:connected to Nature, The Intuition of Nature, Olive Mush, Is That Matty?, and Baby & Mom. Lommel is the region’s largest conservationist and protector of over 30,000 one-hundred-year-old mountain olive trees. With his Thomas Lommel Foundation, he brings the water that he does not use into his waterless beauty products to the people of Africa by building water wells on site.

The company’s direct-to-consumer network includes tens of thousands of Waterless Beauty Consultants in North America and Europe. In addition to online sales and a Europe-wide branch network of thousands of retail stores, Oliveda Deutschland GmbH operates its own flagship stores in Berlin and Düsseldorf.

The brand’s treatment concepts are unique worldwide, and their effectiveness has been confirmed by conventional medicine.  Read our book The Olive Tree Therapy 10 Years in 14 Days. Waterless beauty has been called “The Next Big Thing” in articles in U.S. Vogue, Harper’s Bazaar, InStyle, Elle, Madame, Forbes, and many other industry publications, as well as by Mintel, a world-leading futurology institute.  Gigi Hadid and many other celebrities are already Oliveda fans and support its success.  Further information on Oliveda International, Inc. and its subsidiaries and associate companies and brands can be found at www.olivetreepeople.com

Forward-Looking Statements
This press release may contain statements, estimates or projections that constitute “forward-looking statements” pursuant to the safe harbor provisions of the U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties, which may be found in the Company’s filings with OTC Markets Group Inc., that could cause actual results to differ materially from the Company’s historical experience and present expectations or projections. Investors should not place undue reliance on forward-looking statements, which speak only as of the date they are made.  The Company expressly disclaims any obligation or intention to publicly update or revise any forward-looking statements unless otherwise required by law.

CONTACT: OLVI Investor Relations
619-202-7456
olvi@advanceprgroup.com

Dermatest®-rated skin compatibility “Excellent” and clinical studies by CE.way Regulatory Consultants found significant improvements in skin hydration and elasticity with visible reductions in the appearance of wrinkles in participants

SANTA MONICA, CA, Nov. 12, 2026 (GLOBE NEWSWIRE) — Oliveda International, Inc. (OTCID: OLVI) today announced that the waterless skincare brand, Oliveda, has been awarded “Excellent” ratings from Dermatest® and CE.way Regulatory Consultants alongside four-week clinical results for skin hydration, elasticity and the appearance of wrinkles.

What happens when you build skincare around the olive leaf instead of added water? Oliveda, the waterless skincare brand from Olive Tree People Inc., has been awarded Dermatest’s “Excellent” rating for skin compatibility.

In separate four-week clinical studies, CE.way Regulatory Consultants also rated the tested formulations “Excellent.” The studies found statistically significant improvements in skin hydration and, in formulations evaluated for elasticity, statistically significant improvements in that measure as well (p < 0.05). Facial imaging showed visible reductions in the appearance of wrinkles in some participants.

“We started with a question the beauty industry rarely asks: ‘What could skincare become if we changed the very first ingredient?’” said Thomas Lommel, founder of Olive Tree People. “We built our formulas around the olive leaf. These results show what that decision can mean for skin in just four weeks.”

Oliveda’s approach begins in its own biodynamic olive groves. The brand uses an olive leaf cell elixir containing hydroxytyrosol as the foundation of its waterless skincare. It’s an ingredient Oliveda has worked with for years, and a formulation choice now backed by measured improvements in hydration and elasticity.

About Oliveda
Oliveda is a waterless skincare brand from Olive Tree People, founded by Thomas Lommel. Its formulations draw on ingredients from the company’s own biodynamic olive groves, including olive leaf cell elixir and cold-pressed Arbequina olive oil.

About Olive Tree People
Olive Tree People is a pioneer and leading force in waterless beauty. Instead of using the conventional water phase found in most skincare products, the company replaces water with its proprietary olive leaf cell elixir and combines it with powerful olive-tree ingredients, including Hydroxytyrosol.

Founded by olive tree farmer Thomas Lommel, Olive Tree People develops skincare, beauty and holistic experiences based on more than 20 years of work with mountain olive trees and the principles of Olive Tree Therapy.

About Oliveda International, Inc. 
Oliveda International, Inc. and its subsidiary, Olive Tree People Inc., as well as the European companies, Olive Tree People Europe AG, Oliveda Deutschland GmbH, and Olive Tree Farmers SL, were founded by the German real estate investor Thomas Lommel. The companies possess over 20 years of experience in management and organic certification growing mountain olive trees; in the extraction of first-class, internationally award-winning extra virgin olive oils; the extraction of hydroxytyrosol; and the production and distribution of cosmetic and holistic waterless products related to the olive tree.  Lommel is the inventor of the “Olive Tree Therapy 10 Years in 14 Days” as well as the inventor of olive matcha, which is based on the ground olive leaf. Also unique is the coffee replacement developed by Lommel, which is based on the olive leaf and hydroxytyrosol.  In addition, Lommel is successfully active in the rapidly growing mindfulness industry with the olive tree sound bath meditation he developed and the frequencies of his olive trees, which he makes available worldwide.

In addition to the registered beauty brands, Oliveda and LA Dope, as well as the brands Olive Rose, OLIVE re:connected to Nature, The Intuition of Nature, Olive Mush, Is That Matty?, and Baby & Mom. Lommel is the region’s largest conservationist and protector of over 30,000 one-hundred-year-old mountain olive trees. With his Thomas Lommel Foundation, he brings the water that he does not use into his waterless beauty products to the people of Africa by building water wells on site.

The company’s direct-to-consumer network includes tens of thousands of Waterless Beauty Consultants in North America and Europe. In addition to online sales and a Europe-wide branch network of thousands of retail stores, Oliveda Deutschland GmbH operates its own flagship stores in Berlin and Düsseldorf.

The brand’s treatment concepts are unique worldwide, and their effectiveness has been confirmed by conventional medicine.  Read our book The Olive Tree Therapy 10 Years in 14 Days. Waterless beauty has been called “The Next Big Thing” in articles in U.S. Vogue, Harper’s Bazaar, InStyle, Elle, Madame, Forbes, and many other industry publications, as well as by Mintel, a world-leading futurology institute.  Gigi Hadid and many other celebrities are already Oliveda fans and support its success.  Further information on Oliveda International, Inc. and its subsidiaries and associate companies and brands can be found at www.olivetreepeople.com

Forward-Looking Statements
This press release may contain statements, estimates or projections that constitute “forward-looking statements” pursuant to the safe harbor provisions of the U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties, which may be found in the Company’s filings with OTC Markets Group Inc., that could cause actual results to differ materially from the Company’s historical experience and present expectations or projections. Investors should not place undue reliance on forward-looking statements, which speak only as of the date they are made.  The Company expressly disclaims any obligation or intention to publicly update or revise any forward-looking statements unless otherwise required by law.

CONTACT: OLVI Investor Relations
619-202-7456
olvi@advanceprgroup.com